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ABSTRACT 
This dissertation includes three manuscripts related to peripheral arterial disease.  The first 
examines the effects of assigned glycemic control strategy on the incidence of peripheral arterial 
disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.  
The BARI 2D results show that patients assigned to control their type 2 diabetes with a strategy 
that primarily used insulin sensitizing agents (metformin and/or thiazolidinediones) experienced 
fewer incident cases of peripheral arterial disease than patients assigned to a glycemic control 
strategy that primarily used insulin providing agents.      
 
The second manuscript extends this work by examining risk factors for peripheral arterial disease 
in the BARI 2D trial.  The analyses included traditional cardiovascular risk factors as well as 
biomarkers indicative of inflammation, coagulation, and fibrinolysis.  In patients treated with 
insulin sensitizing medications, biomarkers of inflammation and related processes were 
associated with lower extremity outcomes while this was not the case for patients treated with 
insulin providing medications, a useful mechanistic insight into how the different types of 
diabetes drugs may affect the progression of atherosclerosis. 
 
The third manuscript reports the results of a data collection project evaluating the reproducibility 
and reliability of two methods for measuring the ankle-brachial index.  Reproducibility was 
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iv 
excellent for Doppler-measured ABI, while the Colin oscillometric device showed moderate 
reproducibility.  Agreement between Colin and Doppler was somewhat poor; therefore, we 
would not recommend the Colin device for measuring ABI in clinical settings. 
 
Each manuscript contributes uniquely to public health significance.  The first suggests that a 
glycemic treatment strategy based on insulin sensitizers may reduce the progression of 
atherosclerosis in patients with type 2 diabetes.  The second demonstrated that biomarkers of 
inflammation and fibrinolysis offer additional predictive value over traditional cardiovascular 
risk factors for incidence of PAD in type 2 diabetes patients treated with insulin sensitizing 
medications, implying that different types of glycemic control medications may have different 
mechanistic effects on the progression of atherosclerosis.  The third reinforces current guidelines 
that Doppler ABI should remain the primary diagnostic for PAD in clinical and research settings. 
v 
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 1.0  INTRODUCTION 
Peripheral arterial disease (PAD), also known as peripheral vascular disease (PVD) or lower 
extremity arterial disease (LEAD), is one manifestation of atherosclerosis, a chronic disease that 
is one of the leading causes of death and disability in the United States.1  The chapter that 
follows begins by describing the development of atherosclerosis and how it manifests as PAD.  
Following that, the author presents epidemiological statistics to illustrate the prevalence of PAD, 
the associated morbidity and mortality, and selected risk factors for PAD.  A special section is 
then devoted to PAD in patients with type 2 diabetes mellitus (T2DM), since that patient 
population is a main focus of this research project.  The author also presents a special section 
describing the ankle-brachial index (ABI), which is the principal screening tool for PAD and is 
utilized in all three manuscripts contained within this dissertation.  The section devoted to the 
ABI describes its historical development, the epidemiology of the ABI, a brief description of two 
methods by which ABI can be measured (supplemented by two Appendices that describe the 
respective methods in greater detail), what is known about the comparability of these two 
methods, and finally a section describing current guidelines for whom should have an ABI 
measurement as well as the clinical significance of the ABI. 
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 1.1 PERIPHERAL ARTERIAL DISEASE 
1.1.1 Pathophysiology 
Atherosclerosis is a complex disease that involves lipid disturbances, endothelial dysfunction, 
inflammation, vascular remodeling, and the development of lesions in the arterial wall.2,3,4  The 
symptoms and ultimate consequences of an atherosclerotic lesion are dependent on factors such 
as the location, size, and stability of the lesion.  Atherosclerotic lesions are most prevalent in the 
coronary arteries but can also be present in the brain, kidneys, and lower extremities.5 
 
The atherosclerotic process begins when endothelial cells over-express certain molecules in the 
setting of an unfavorable serum lipid profile.2,3 These molecules, known as adhesion molecules, 
include P-selectins and E-selectins, intercellular adhesion molecules (ICAM), and vascular-cell 
adhesion molecules (VCAM).6  Adhesion molecules promote the migration of leukocytes, the 
release of cytokines, and the recruitment of monocytes into the intimal layer of the artery; the 
recruitment of monocytes into the intima provokes an inflammatory response. 
 
The inflammatory response stimulates the migration and proliferation of smooth muscle cells in 
the area of injury.  Concurrently, monocytes in the intima develop into macrophages, which are 
mediators of the inflammatory response and directly contribute to the atherosclerotic process.  
The uptake of modified lipoproteins by macrophages leads to the accumulation of cholesterol 
esters and formation of macrophage-derived “foam cells” within the arterial wall.  The ensuing 
accumulation of lipid-laden cells is referred to as the “fatty streak” (Figure 1-1), the earliest 
visible lesion in the atherosclerotic process. 
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Figure 1-1. Fatty-Streak Formation in Atherosclerosisa 
 
Platelet adhesion is another characteristic of the atherosclerotic process.  Platelets can adhere to 
dysfunctional endothelium, exposed collagen, and macrophages.  When activated, platelets may 
release their granules, which contain cytokines and growth factors that may contribute to the 
migration and proliferation of smooth muscle cells and monocytes. 
 
Initially the only cells thought to proliferate during expansion of atherosclerotic lesions were 
smooth-muscle cells.  However, replication of the monocyte-derived macrophages and T cells 
may also be involved.7  The macrophages’ ability to produce cytokines, proteolytic enzymes, and 
growth factors may be critical in the cycle of damage and repair that ensues as lesions progress. 
With time, the fatty streak evolves into a fibrous plaque.8  The plaque enlarges gradually over 
time with continued accumulation of foam cells, which may also accumulate additional lipids.  
a Reprinted with permission from Ross R, N Engl J Med 1999; 340: 115-126.  Copyright Massachusetts Medical Society. 
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 Continued proliferation of smooth muscle cells and intracellular matrix produce the definitive 
plaque, covered by a fibrous cap (pictured in Figure 1-2).  Acute arterial events occur if the 
fibrous cap is disrupted; the resulting exposure of the prothrombotic lipid core and 
subendothelial tissue leads to thrombus formation and flow occlusion.   
 
Figure 1-2. Advanced Plaque Formation in Atherosclerosisb 
 
During the development of an atherosclerotic plaque, the entire vessel may enlarge in size to 
maintain normal blood flow through the lumen, a phenomenon known as vascular remodeling.  
However, once the plaque enlarges to approximately 40% of the vessel diameter, the artery can 
no longer compensate by vasodilation and the lesion begins to intrude into the lumen.  When a 
hemodynamically significant stenosis is present in the lower extremity, distal pressure and flow 
are reduced, defining a case of peripheral arterial disease. 
 
b Reprinted with permission from Ross R, N Engl J Med 1999; 340:115-126.  Copyright Massachusetts Medical Society. 
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 The most frequent presenting symptom in patients with PAD is intermittent claudication, which 
is defined as pain in the leg muscles with ambulation. Claudication is caused by arterial 
obstruction proximal to affected muscle beds, which limits the normal exercise-induced increase 
in blood flow and produces transient muscle ischemia during exercise.9  Many patients with 
advanced PAD experience some symptoms of intermittent claudication; however, some elderly 
patients assume that leg pain while walking is part of the normal aging process and do not report 
their symptoms.  Claudication symptoms are typically localized in the calf or thigh, although 
pain may begin to appear in the foot for patients with severe cases.  In advanced stages of PAD, 
tissue perfusion progresses to ischemic ulceration or gangrene, known as critical limb ischemia 
(CLI).  It is estimated that there is about one annual case of CLI per 100 patients with 
intermittent claudication.  The prognosis is extremely poor for these patients; one-year mortality 
is approximately 25% and major amputation is eventually required in about 50% of CLI 
patients.10  This is discussed further in Section 1.1.3 on morbidity and mortality. 
 
Not all patients undergoing a lower-extremity amputation have experienced a steady progression 
from claudication to rest pain to CLI to amputation.  A 1984 review of 713 patients undergoing 
below-knee amputations for ischemia found that more than half had experienced no ischemic 
symptoms as recently as 6 months before the amputation.11  This seems counterintuitive, because 
atherosclerosis is a chronic disease that develops over years rather than months, but it 
demonstrates the complex disease pathology of claudication in PAD patients.  One may conclude 
that many patients with peripheral atherosclerosis will be asymptomatic until the disease is quite 
advanced, highlighting the importance of screening patients with the ankle-brachial index. 
5 
1.1.2 Prevalence 
PAD is typically asymptomatic in its early stages, so it is difficult to ascertain the population 
prevalence in the absence of widespread screening.  It is also difficult to compare prevalence 
estimates because the criterion used to define PAD has evolved over time.12,13,14 The most 
reliable prevalence estimate likely comes from a 2007 manuscript written by Allison et al which 
pooled data from seven community-based studies, applying the studies’ age- and ethnic-specific 
rates to the 2000 U.S. census to estimate population prevalence.15  This method estimated that at 
least 6.8 million individuals aged 40 years or older had PAD, approximately 5.8% of the U.S. 
adult population.  According to Allison et al, the prevalence of PAD approximately doubled with 
each 10-year age increase among adults over 40 years old.  This relationship was consistent in all 
racial/ethnic categories and held true for both men and women (Figure 1-3).    
Figure 1-3. Ethnic-Specific Prevalence of Peripheral Arterial Disease in Men and Womenc 
c Reprinted with permission from Allison et al, Am J Prev Med 2007; 32: 328-333 
6 
Also visible on Figure 1-3 is that African-Americans tended to have greater risk of PAD than 
other racial/ethnic groups in Allison’s pooled study.  This held true for both men and women, 
and the increased risk among African-Americans was especially noticeable in the elderly.  The 
higher risk among African-Americans in older age groups is consistent with prior research from 
the Systolic Hyptertension in the Elderly Program (SHEP),16 which was a clinical trial evaluating 
the efficacy of drug therapy for systolic hypertension in the elderly.  All participants were at least 
60 years old at enrollment and had isolated systolic hypertension, which defines a population 
with especially high risk for PAD.  The ankle-brachial index was measured at 11 of the 16 SHEP 
field centers as part of an ancillary study to assess the prevalence of PAD and risk factors which 
might be associated with PAD in the SHEP study population.  Participants self-identified as 
Black race had greater prevalence of PAD than White study participants in all age categories 
among both men and women.  In a multivariable logistic regression which adjusted for potential 
confounders (age, smoking, body mass index, diabetes, systolic blood pressure, HDL cholesterol, 
and existing coronary artery disease) there was a significantly greater risk of PAD in Blacks 
compared to White participants (OR=2.51, 95% CI: 1.84-3.41, p<0.001).  Therefore, we 
conclude that the strong relation of PAD with Black race was not explained by differences in 
baseline characteristics between the racial categories.  The SHEP investigators also found that, 
among Blacks, subgroups that were expected to be at low risk for PAD were not.  For example, 
Blacks who never smoked had nearly twice the prevalence of PAD as Whites who never smoked.  
The National Health and Nutrition Examination Survey (NHANES) data have also been used to 
estimate the prevalence of PAD in the United States.  Carried out primarily using surveys, the 
7 
NHANES sample is created using a multistage probability sample of the noninstitutionalized 
civilian United States population designed to oversample the elderly, low-income persons, 
adolescents, Mexican Americans, and non-Hispanic blacks to provide more reliable estimates for 
these population subgroups.  NHANES 1999–2000 was the first NHANES survey to perform 
ankle-brachial blood pressure measurements on participants, analyzed by Selvin et al14 to 
estimate the prevalence of PAD in the year 2000.  According to the NHANES 1999-2000 data, 
the prevalence of PAD among individuals aged 40 years or older was 4.3% (95% CI 3.1% to 
5.5%) in the year 2000, translating to an estimated 5 million adults (95% CI 4 to 7 million) who 
would be classified as having PAD.  Parallel to the SHEP results, the NHANES data suggested 
that PAD disproportionately affects older individuals and Blacks, and the excess PAD 
prevalence among Blacks was not explained by other known risk factors.  Selvin et al also 
performed additional analyses to examine the relationships between PAD and other risk factors; 
NHANES data will be referenced further in Sections 1.1.4 (traditional risk factors), 1.1.5 (novel 
risk factors) and 1.2.1 (PAD in patients with type 2 diabetes mellitus) where appropriate. 
The Atherosclerosis Risk in Communities (ARIC) study17 also reported the prevalence of PAD in 
various racial/ethnic subgroups.  The ARIC study was a longitudinal investigation designed to 
assess the natural history and etiology of preclinical and clinical atherosclerotic disease by age, 
race/ethnicity, and gender. The ARIC cohort was sampled from four U.S. communities (Forsyth 
County, NC; Jackson, MS; Minneapolis MN; and Washington County, MD) and participants 
were selected by a probability sample of eligible adults aged 45 to 64 to provide a total of 15,792 
men and women.  The ARIC data also showed that Black race was associated with increased risk 
of PAD in all age categories for both men and women (see Figure 1-4).   
8 
  
Figure 1-4. Prevalence of Peripheral Arterial Disease in the Atherosclerosis Risk In 
Communities (ARIC) Studyd 
 
According to the studies presented here, prevalence of PAD appears to be essentially equivalent 
in men and women.  Neither the SHEP data nor the NHANES data showed any consistent gender 
differences in PAD prevalence, and the ARIC data generally showed a similar prevalence of 
PAD when comparing men to women of the same ethnicity and age group (Figure 1-4).  Allison 
et al’s pooled study (Figure 1-3) showed that men had slightly higher rates of PAD than women 
overall, but also noted that women seemed to have higher prevalence of PAD in the younger age 
categories, while older men tended to have higher prevalence than women of the same age and 
ethnic group.  Therefore, it appears that overall prevalence is approximately equivalent between 
men and women. 
d Reprinted with permission from Zheng et al, Am J Prev Med 2005; 29: 42-49. 
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 1.1.3 Morbidity and Mortality 
PAD directly increases the risk of functional limitation, physical disability, leg revascularization, 
and amputation.18,19,20 While a relatively small proportion (1-3%) of patients with PAD present 
with critical limb ischemia (CLI), the prognosis for a patient with such advanced disease is 
extremely poor, with an estimated 25% one-year mortality rate and an additional 30% of patients 
presenting with CLI likely to undergo amputation within one year (Figure 1-5).  Following an 
amputation, quality of life tends to suffer as a result, primarily owing to the restricted mobility.21   
 
 
Figure 1-5. Natural History of Peripheral Arterial Diseasee  
e Reprinted with permission from Hirsch et al. Circulation 2006; 113: 1474-1547. 
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 PAD is not only a condition unto itself, but the presence of PAD is also a marker of generalized 
systemic atherosclerosis, and therefore PAD is associated with increased risk of cardiovascular 
and all-cause mortality.22,23,24,25,26,27  Estimates of the excess mortality risk associated with PAD 
vary based on the age distribution and disease status of the population in question, but it is clear 
that patients with PAD consistently have higher mortality risk than those free of PAD in all 
populations.  Figure 1-6 below shows the precipitous decrease in five- and ten-year survival for 
patients with intermittent claudication or critical limb ischemia; the mortality risk associated with 
asymptomatic PAD will be discussed in more detail in Section 1.3 on the ankle-brachial index. 
 
 
Figure 1-6. Estimated Survival for Patients with Advanced Peripheral Arterial Diseasef 
 
Admittedly, the relationship between PAD and cardiovascular mortality must be considered in 
the context of possible coexisting atherosclerosis in other vascular beds.  The cause of death in 
f Reprinted with permission from Norgren et al, Eur J Vasc Endovasc Surg 2007; 33: S1-S70. 
*IC= Intermittent Claudication; CLI = Critical Limb Ischemia 
11 
                                                 
 PAD patients is often something other than the lower extremity disease itself, such as coronary 
artery disease (CAD).  Approximately half of patients with PAD have coexisting CAD.28  
However, the relationship between PAD and other CVD events make it a useful marker of 
disease as well as a condition that must be monitored in its own right; a recommended treatment 
algorithm29 for peripheral arterial disease is shown below (Figure 1-7). 
 
Figure 1-7. Treatment Algorithm for Patients with Known Peripheral Arterial Diseaseg 
g Reprinted with permission from Hiatt et al N Engl J Med 2001; 334: 1608-1621. Copyright Massachusetts Medical Society. 
12 
                                                 
 1.1.4 Traditional Cardiovascular Risk Factors 
PAD is generally asymptomatic in its early stages, but it is easily detected by screening at-risk 
patients with an ankle-brachial index (ABI).  Therefore, to improve early detection of PAD, 
knowledge of risk factors is critical to ensure that high-risk patients are screened with an ABI.28  
Many of the known risk factors for PAD are well-established as risk factors for atherosclerosis in 
all vascular beds, although the magnitude of some risk factors’ effects may vary between PAD 
and other atherosclerotic processes.  As demonstrated in Figure 1-7, the immediate steps taken 
to reduce cardiovascular risk in a patient with diagnosed PAD include smoking cessation, 
treatment of dyslipidemia, treatment of hypertension, and glucose lowering, with additional 
emphasis on treating these risk factors if a patient is diabetic or has renal disease.  Smoking, 
dyslipidemia, hypertension, elevated glucose (diabetes), and renal disease are all established risk 
factors for cardiovascular disease at large; each will be discussed briefly here. 
 
Cigarette smoking is the strongest risk factor for both onset and progression of PAD, with 
estimates ranging from about a twofold greater risk to a fivefold greater risk in current smokers 
compared to non-smokers. 14,30,31,32  The NHANES 1999-2000 data showed a significantly 
increased risk of PAD (OR=4.23, 95% CI 1.95-9.17, p<0.05) for current smokers compared to 
nonsmokers.  The relative risk associated with smoking varies due to differences in study 
population; smoking increases risk the most in younger, otherwise healthy populations, while the 
effect is somewhat smaller in older populations that have a larger overall prevalence of PAD.  
Physiologically, smoking impairs vasodilation and attenuates production of endothelium-derived 
nitric oxide (NO), both of which retard the development of atherosclerosis, and therefore 
13 
 smoking increases risk of atherosclerosis in all vascular beds.33  Cigarette smoking is more 
strongly associated with PAD than it is with coronary disease, although the reason is unknown.  
Therefore, all adult smokers should be considered at high risk for PAD. 28 
 
Hypertension is also strongly associated with PAD14,34 showing approximately 1.5- to three-fold 
increases in risk, again depending on age and composition of the study population.  The 
aforementioned NHANES 1999-2000 data showed a moderately increased risk of PAD 
(OR=1.75, 95% CI 0.93-3.30), although this was not significant in a fully adjusted model.  
Hypertension promotes the development of atherosclerotic plaques by its effects on the 
vasculature: arteries exposed to hypertension have increased permeability, allowing oxidized 
lipoproteins to migrate into the intima.35  There is also evidence suggesting that hypertension 
alters the balance between cellular proliferation and apoptosis.36  Obviously, since systolic blood 
pressure is a component of the ankle-brachial index, it would be expected to have some 
association with PAD risk. This is discussed further in Section 1.3 on the ABI. 
 
Dyslipidemia is associated with increased risk of PAD, but the magnitude of this relationship is 
somewhat smaller than that observed for smoking and hypertension. 14,37 NHANES 1999-2000 
data showed a significantly increased risk of PAD (OR=1.67, 95% CI 1.01-2.74, p<0.05) for 
participants with hypercholesterolemia.  Our view of the role of lipids in atherosclerosis has 
evolved over the past several decades, but it has long been established that higher levels of LDL 
cholesterol are associated with increased cardiovascular risk, while higher levels of HDL 
cholesterol are protective.38  The form of dyslipidemia most common in PAD patients is the 
14 
 combination of low HDL cholesterol and elevated triglyceride levels commonly seen in patients 
with diabetes.30  
 
Renal insufficiency is also common in patients with PAD and vice versa.39  However, the 
causality of this relationship is not entirely clear.  The NHANES data40 showed that the 
prevalence of low ABI was six times greater in patients with low creatinine clearance, and this 
relationship remained significant after adjusting for known PAD risk factors.  The association 
between chronic kidney disease (CKD) and PAD is independent of age, ethnicity, diabetes, and 
hypertension, and although the exact reason is not known, it may relate to the vascular 
inflammation and elevated homocysteine levels seen in CKD.37  However, it is uncertain whether 
i) there is a true causal relationship between CKD and PAD or ii) the frequent coexistence of the 
two diseases is a reflection of the systemic complications of both atherosclerosis and CKD. 
 
Peripheral arterial disease is also especially common in patients with type 2 diabetes mellitus 
(T2DM).14,41  The clinical presentation of PAD also tends to differ in T2DM patients compared 
to those free of diabetes.  It is believed that the abnormnal cluster of hyperglycemia, elevated 
free fatty acids, and insulin resistance observed in T2DM promotes oxidative stress and 
endothelial dysfunction, both of which contribute to atherosclerosis.  Insulin resistance also 
intensifies the systemic inflammatory state, promotes thrombosis, and constrains fibrinolysis.42  
The American Diabetes Association recommends a screening ABI every 5 years in patients with 
diabetes.43 The relationship between PAD and T2DM will be discussed in much greater depth in 
Section 1.2 of this document.   
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 Notably, body mass index has generally shown little association with PAD when adjusting for 
other cardiovascular risk factors.14,16 Given the strong association between obesity and coronary 
artery disease, the lack of association between obesity and PAD is somewhat counterintuitive.  
One hypothesis is that PAD is detected less often among obese patients because the principal 
diagnostic, the ankle-brachial index, is less sensitive in obese patients because the size of their 
ankles makes it difficult to take an accurate blood-pressure reading at the ankle (discussed 
further in Section 1.3 on the ankle-brachial index).  Another possibility is that obese patients tend 
to be less physically active than normal-weight patients and therefore less likely to experience 
symptoms of claudication that would prompt a physician to examine the patient further. 
 
As reviewed in this section, cigarette smoking, hypertension, dyslipidemia, renal insufficiency, 
and diabetes are independently associated with peripheral arterial disease.  However, treatment 
targets for these risk factors are generally driven by their respective associations with coronary 
artery disease; furthermore, since these relationships are already well-documented, further study 
of these relationships is unlikely to provide a great deal of new information.  However, it would 
be useful to identify additional risk factors beyond the traditional cardiovascular disease risk 
factors that may enhance our understanding of the pathophysiology of peripheral arterial disease, 
which may eventually lead to potential therapeutic targets for further study. 
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 1.1.5 Novel Risk Factors 
Inflammation, coagulation, and fibrinolysis are interconnected processes43 and markers related to 
each process are associated with coronary atherosclerosis44,45 and peripheral arterial disease.46,47 
Several biomarkers of these three processes are associated with PAD in existing cross-sectional 
studies, but few of these relationships have been confirmed with data from longitudinal studies.  
The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial has 
longitudinal data on biomarkers related to these processes as well as data on PAD and related 
outcomes during follow-up.  These data could be used to examine which of these biomarkers are 
associated with incident PAD in a population with existing coronary atherosclerosis, which could 
help us better understand the systemic atherosclerotic process.  The rationale for each 
biomarker’s relationship with atherosclerosis (and, by extension, the risk of developing PAD) 
will be discussed briefly here. 
 
C-reactive protein (CRP), a marker of inflammation, binds to endothelial cell receptors and also 
co-localizes with oxidized LDL in atherosclerotic plaques.48 CRP also promotes leukocyte 
adhesion and stimulates endothelial production of procoagulant tissue factor,49 both of which 
contribute to an atherogenic environment.  CRP also increases production of compounds that 
impair fibrinolysis such as plasminogen activator inhibitor-1 (PAI-1)50 and inhibits tissue-type 
plasminogen activator (t-PA),51 discussed in the section that follows.  The associations between 
CRP and these biomarkers illustrate the complexity of the relationship between inflammation, 
coagulation, and fibrinolysis.  Although discussed with “novel” risk factors for the purposes of 
this document, C-reactive protein is well established as a risk factor for cardiovascular disease.52   
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According to Ridker’s seminal paper, CRP evaluation may have the potential to improve 
cardiovascular risk prediction models when used as an adjunct to this approach.  For each 
quintile increase in CRP, the adjusted relative risk of suffering a future cardiovascular event is 
estimated to be 26% for men (95% CI 11% to 44%; P<0.005) and 33% for women (95% CI 13% 
to 56%; P<0.001).  There is also some evidence linking CRP specifically to PAD: NHANES 
1999-2000 data also showed that patients in the highest quartile of CRP had a greater risk than 
patients in the lowest quartile, although the difference was not statistically significant when 
adjusting for other cardiovascular risk factors (OR=1.72, 95% CI 0.74-3.99). 
 
CRP is a marker of inflammation, but as mentioned above it might influence the atherosclerotic 
process by increasing production of compounds that impair fibrinolysis, a process in which a 
fibrin clot, the product of coagulation, is broken down (see Figure 1-8). The acute fibrinolytic 
response to inflammation and coagulation is the release of plasminogen activators.  Tissue-type 
plasminogen activator (t-PA) is an enzyme found on endothelial cells which catalyzes the 
conversion of plasminogen to plasmin, which is the major enzyme responsible for breakdown of 
blood clots.53  The increase in plasminogen activation and subsequent plasmin generation 
stimulated by t-PA is counteracted by a delayed but sustained increase in plasminogen activator 
inhibitor-1 (PAI-1),54 a protein that functions as the principal inhibitor of t-PA and hence is an 
inhibitor of fibrinolysis.   
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Figure 1-8. Biomarkers' Role In Fibrinolysis 
 
Increased expression of PAI-1 is believed to accelerate the development of atherosclerosis and 
shifts the balance between thrombosis and fibrinolysis.55  Increased expression of PAI-1 also is 
suggestive of insulin resistance and has been associated with vascular inflammation.56 Lower 
concentrations of t-PA and greater expression of PAI-1 have each been associated with increased 
risk of arterial thrombosis.57,58,59 Since lower levels of t-PA and/or increased expression of PAI-
1 are associated with various aspects of the atherosclerotic process as well as thrombotic arterial 
events, one might expect that they also could be associated with increased risk of PAD. 
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 Another marker of fibrinolysis is fibrinogen, a soluble plasma glycoprotein that is converted into 
fibrin during coagulation.  Fibrinogen is thus a major component of the coagulation cascade and 
may affect the formation of atherosclerotic plaques through a number of different pathways: 
fibrinogen promotes the binding and production of high-density lipoproteins,60 facilitates the 
migration of adhesion molecules to the endothelial surface,61 initiates the proliferation and 
migration of smooth muscle cells,62 and mediates the binding of monocytes and endothelial cells 
through ICAM-1 and MAC-1.63 Fibrinogen can also stimulate expression of proinflammatory 
cytokines on mononuclear cells and induce production of chemokines by endothelial cells and 
fibroblasts.64  While fibrinogen is not a primary therapeutic target or first-line screening test, it is 
well established as a risk factor for cardiovascular disease.65  There is also some evidence linking 
fibrinogen to increased risk of PAD; NHANES 1999-2000 data showed that patients in the 
highest quartile of fibrinogen had a greater PAD risk than patients in the lowest quartile of 
fibrinogen, although the difference was not statistically significant when adjusting for other 
cardiovascular risk factors (OR=1.68, 95% CI 0.67-4.23). 
 
Fibrinogen is converted into fibrin during coagulation; emerging on the other side of the 
fibrinolytic process is the fibrin degradation product known as D-dimer, a small protein fragment 
which contains two crosslinked D fragments of the fibrinogen protein.66  D-dimers are not 
normally present in human blood plasma except when the coagulation system is activated; its 
principal use in diagnostic testing is to rule out thrombotic events.  However, since the plasma 
level of D-dimer is a marker of coagulant and subsequent fibrinolytic activity,67 increased D-
dimer might also be associated with increased risk of PAD.  Plasma levels of D-dimer are 
generally correlated with t-PA and PAI-1 activity.68  However, D-dimer, t-PA and PAI-1 reflect 
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 different aspects of the fibrinolytic system and thus each might provide unique information about 
the atherosclerotic process.  
 
There is a plausible biological hypothesis linking each of the aforementioned biomarkers with 
developing atherosclerosis, but only C-reactive protein, fibrinogen, and D-dimer have been 
identified as risk factors for incident PAD in epidemiological studies.  NHANES 1999-2000 data 
showed that participants in the highest quartile of CRP and fibrinogen had two-fold increased 
risk of prevalent PAD compared with participants in the lowest quartiles.69 Both fibrinogen and 
D-dimer have been associated with increased risk of PAD in cross-sectional studies.46,70,71 
Fibrinogen and D-dimer were also linked to the progression of PAD in the Edinburgh Artery 
Study;72 however, neither was significantly associated with PAD progression after adjusting for 
the level of CRP, suggesting that the processes of inflammation, coagulation, and fibrinolysis 
may not contribute “independently” to the progression of systemic atherosclerosis but instead 
that the processes may be reflective of an overall advancing disease state. 
 
The increased risk associated with higher levels of the respective biomarkers is not isolated to 
“incident” disease but also extends to poorer outcomes among individuals with existing PAD.  In 
patients with existing PAD, the aforementioned biomarkers have been associated with increased 
risk of functional decline, failure of lower-extremity revascularization procedures, cardiovascular 
mortality and all-cause mortality.73,74,75,76,77,78,79 Although these studies combine to suggest that 
inflammation, coagulation, and fibrinolysis may affect the progression of PAD, most of the 
existing studies are not ideally suited to describe the association between changes in biomarker 
levels and PAD outcomes because they are one of the following designs: 
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i) cross-sectional studies linking current levels of a biomarker to “prevalent” PAD; while 
this is a useful exploratory analysis, this study is not well-suited to elucidate temporality. 
 
ii) longitudinal studies whereby a “baseline” level of the risk factor is linked to risk of 
incident PAD.  This is highly useful to establish risk factors for future disease, but it 
would be useful to quantify the relationships between time-varying changes in markers of 
inflammation, coagulation, and fibrinolysis and the incidence of PAD to determine 
whether changes in any of these markers provide additional predictive value.   
 
Further study of the association between these biomarkers of inflammatory states and impaired 
fibrinolysis may improve our understanding of their effects on the development of peripheral 
atherosclerosis.  The next step in understanding these relationships would be a study with these 
biomarkers examined as time-varying covariates to elucidate how changes in biomarkers profiles 
may be associated with PAD and/or developing atherosclerosis.  If time-varying changes in 
selected biomarkers show a significant association with disease, we may be able to better target 
high-risk patients who should be screened and/or treated for PAD, and we may also better 
understand the mechanism by which atherosclerosis continues to progress throughout the 
vasculature in patients with type 2 diabetes mellitus, discussed in the following section. 
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 1.2 PERIPHERAL ARTERIAL DISEASE IN TYPE 2 DIABETES 
Peripheral arterial disease is highly prevalent in patients with Type 2 Diabetes Mellitus (T2DM).  
Furthermore, PAD typically presents earlier and progresses more rapidly in T2DM patients than 
in nondiabetic patients.  The epidemiology, clinical presentation, and potential mechanisms of 
peripheral arterial disease in type 2 diabetes mellitus are discussed below. 
1.2.1 Epidemiology 
It is well-established that diabetes mellitus is associated with an increased risk of all types of 
cardiovascular disease, including peripheral arterial disease.  Part of this is likely attributable to 
the multifactorial cluster of additional risk factors that often accompany diabetes, such as 
hypertension and dyslipidemia.  However, elevated glucose levels are generally associated with 
increased risk of atherosclerotic disease even after adjustment for coexisting risk factors. 
 
The NHANES data suggest that T2DM patients had approximately threefold greater risk of PAD 
than those free from diabetes.14 Patients with diabetes often present with more advanced PAD 
and experience worse PAD outcomes than nondiabetic patients.80  Peripheral arterial disease in 
patients with diabetes is associated with substantial functional impairment and adversely affects 
quality of life.81 PAD patients with diabetes have a higher risk of leg revascularization and 
amputation than those without diabetes. 82,83,84  Compared to nondiabetic patients, T2DM 
patients with coexisting PAD have a significantly increased risk of cardiovascular mortality.85,86 
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 1.2.2 Clinical Presentation 
The increased risk of PAD in diabetic patients is likely due to the abnormal metabolic state that 
prevails in T2DM.  The abnormnal cluster of hyperglycemia, elevated free fatty acids, and 
insulin resistance characteristic of patients with diabetes results in oxidative stress and 
endothelial dysfunction, states that promote the development of atherosclerostic plaques.  As a 
result, the distribution of PAD tends to differ slightly between diabetic and nondiabetic patients.  
Diabetic patients frequently show involvement of the arteries below the knee, especially the 
tibial and peroneal arteries, and PAD is more commonly multi-segmental in diabetic patients. 84 
 
Mobility is especially poor for diabetic patients with PAD.  These patients generally have poorer 
function than nondiabetic patients with PAD, exhibited by shorter mean walking distance and 
slower walking velocity.81 This may be due to associated peripheral neuropathy, differences in 
exertional leg symptoms, and overall greater cardiovascular disease burden in diabetic patients.  
The decrease in mobility may affect health status and quality of life.20 
 
Some diabetic patients with peripheral neuropathy will have decreased pain perception that may 
delay the recognition of PAD.87  Peripheral neuropathy and PAD are both known risk factors for 
foot ulceration and gangrene; patients with both conditions are extremely likely to experience a 
poor outcome.  An estimated 40-60% of diabetic patients with foot ulcers have PAD, which 
affects wound healing and leads to the need for revascularization, amputation and possibly 
mortality.88  Development of dry gangrene is the end-stage presentation of PAD; once disease 
has advanced to this point, a revascularization and/or a major amputation will be required. 
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 1.2.3 Potential Mechanisms 
Several studies have shown that high levels of glycosylated hemoglobin (HbA1c) are 
independently associated with increased risk of PAD in T2DM.  Data from the National Health 
and Nutrition Examination Survey (NHANES) 1999-2002 showed a positive dose-response 
relationship between HbA1c and risk of PAD, with a 2.3-fold relative risk for diabetic patients 
with HbA1c<7% and a 2.7-fold relative risk for diabetic patients with HbA1c≥7% compared to 
nondiabetic patients.89  The United Kingdom Prospective Diabetes Study (UKPDS) showed that 
each 1% increase in HbA1c was associated with a 28% increased risk of PAD.90,91  The 
increased risk of PAD incidence associated with poor glycemic control carries over to an 
increased risk of severe PAD events; data from the Atherosclerosis Risk in Communities (ARIC) 
study showed that the risk of PAD-related hospitalization was 4.5 times greater among patients 
in the highest HbA1c tertile than the risk among patients in the lowest HbA1c tertile.92 
 
Despite the association between HbA1c and PAD risk, trials of intensive glucose control have 
thus far failed to demonstrate a significant benefit on most cardiovascular outcomes, including 
PAD.93  The Veterans Affairs Diabetes Trial (VADT),94  the Action to Control Cardiovascular 
Risk in Diabetes (ACCORD) trial95 and the Action in Diabetes and Vascular Disease: Preterax 
and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial96 all failed to 
demonstrate a benefit of intensive glucose-lowering therapy on macrovascular outcomes, despite 
achievement of significantly lower HbA1c levels in those assigned to intensive therapy.  
Although HbA1c is a marker of PAD risk, there is no conclusive evidence that lowering HbA1c 
reduces the risk of PAD.   
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 If glucose control is not the driving factor in PAD risk for T2DM patients, then some other factor 
may increase the risk of PAD in this population.  Some of the unexplained variation in PAD risk 
among T2DM patients might be due to the insulin resistance which prevails in T2DM.  Insulin 
resistance intensifies the systemic inflammatory state, is prothrombotic, and constrains 
fibrinolysis;42 as mentioned in the preceding section, these respective processes are thought to be 
involved in the atherosclerotic process.  Elevated fibrinogen has been associated with increased 
risk of PAD in patients with diabetes,97 but no other studies have specifically examined these 
relationships in T2DM patients.  Results from the aforementioned BARI 2D trial have shown 
that glycemic control strategy focused on improving insulin sensitivity led to changes in 
biomarker profiles indicative of a profibrinolytic, antithrombotic, and anti-inflammatory state.98 
If longitudinal changes in biomarkers of inflammation, coagulation, and fibrinolysis account for 
some of the variation in PAD risk, that may i) partially explain the mechanism of increased risk 
of PAD in T2DM patients and ii) suggest a pathway by which insulin sensitizers reduce the risk 
of incident PAD, thereby slowing the progression of atherosclerosis in T2DM. 
 
Prior reviews have speculated that insulin sensitizing medications may reduce the risk of incident 
PAD in T2DM because of their anti-inflammatory properties and metabolic effects.99,100,101 
However, no published data from randomized controlled trials has confirmed this belief.  Data 
from a randomized controlled trial showing that insulin sensitizing medications reduce the risk of 
PAD independent of changes in glycemic control would suggest that improvements in 
macrovascular outcomes may be achieved by changing the mechanistic approach to focus on 
insulin sensitivity. 
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 1.3 ANKLE BRACHIAL INDEX 
The ankle-brachial index (ABI) is the principal non-invasive screening technique for peripheral 
arterial disease.  Also known as ankle-arm index (AAI) or ankle-brachial pressure index (ABPI), 
the ABI is simply a ratio of the brachial systolic blood pressure divided by the ankle systolic 
blood pressure.  Normal ABI values range from 0.91-1.30; an abnormally low ABI is suggestive 
of peripheral arterial disease.  The origin, epidemiology, measurement, and clinical significance 
of the ABI are summarized in the sections to follow. 
1.3.1 Origin 
Ankle blood pressure first appeared in medical literature in 1950.  University of Southern 
California physician Travis Winsor reported taking a series of systolic pressure measurements in 
patients with peripheral arterial disease, including measurements at the ankle, and showed that 
the gradient of pressure reduction along the arterial tree was greater for patients with peripheral 
arterial disease than patients with normal arteries.102  In 1956, Gaskell used ankle systolic 
pressure to evaluate blood flow before and after an arterial graft in the lower extremity.103  
Strandness and colleagues published a series of articles from 1961-66 using ankle systolic 
pressures to study various aspects of the occlusive process in the extremities.104,105,106 
 
The first study to report the ratio of ankle pressures to brachial pressures was published in 1968.  
Canadian physician Stefan Carter reported that patients with normal arteries generally presented 
with an ankle systolic pressure ranging from 100 to 120% of their brachial systolic pressure 
(corresponding to an ABI of 1.0-1.2), while all patients with peripheral arterial disease had ankle 
pressures below 80% of their brachial pressure (corresponding to an ABI of 0.8 or less).107  
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 Carter’s paper also provided statistical evidence that ABI values were lower in patients with 
peripheral arterial disease than in patients without PAD.  The following year, Carter showed that 
the degree of decrease in ABI was correlated with severity of the occlusion among patients with 
peripheral arterial disease.108  In 1970, Yao et al confirmed that severity of occlusion was 
correlated with degree of decrease in ABI; this study was also the first to report measuring ankle 
pressures using the Doppler ultrasound technique still used today.109,110 
1.3.2 Epidemiology 
The ankle-brachial index was established as a useful tool for the evaluation of peripheral arterial 
disease by the end of the 1960’s, but its potential utility as a screening tool for cardiovascular 
risk was not established for many years.  The relationship between ankle-brachial index and 
cardiovascular outcomes was first reported in a large epidemiological study in the early 1990’s. 
 
In 1991, McKenna et al published data from a cohort of 744 patients showing that patients with 
ABI ≤ 0.85 had a relative risk of mortality 2.36 times greater than patients with ABI > 0.85, the 
first published result to suggest that a low ankle-brachial index was associated with increased 
mortality risk.111 Two years later, Newman et al published similar results from 1537 subjects 
enrolled in the Systolic Hypertension in the Elderly Program (SHEP) showing that ABI ≤ 0.9 
was strongly associated with total mortality (age-adjusted RR=4.1) and cardiovascular mortality 
(age-adjusted RR=3.7).112,113 In 1996, Leng et al published data from the Edinburgh Artery 
Study showing that low ankle-brachial index was independently associated with coronary heart 
disease and myocardial infarction.114 Data from the Framingham Study established that low ABI 
was also associated with an increased risk of stroke.115  In addition to the associations with 
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 cardiovascular mortality and all-cause mortality, low ankle-brachial index is also associated with 
limited physical function (Figure 1-9).18 
 
 
Figure 1-9. Patients Stopping during 6-minute walk test according to ABI Categoryh 
 
Most early studies focused on the risk in patients with a low ankle-brachial index; each of the 
studies described on the previous page compared patients with low ABI to the rest of the 
respective study cohort.  However, more recent research has examined risk across the entire ABI 
spectrum, demonstrating that high ABI may also be indicative of increased cardiovascular risk. 
 
h Reprinted with permission from McDermott MM et al.  Ann Intern Med 2002; 136: 873-883 
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Figure 1-10. All-Cause and Cardiovascular Mortality Across the Spectrum of Ankle-
Brachial Index in the Strong Heart Studyi 
 
In 2004, Resnick et al116 published data from the Strong Heart Study showing that patients with 
ABI > 1.4 also had higher risk of cardiovascular events and all-cause mortality compared to 
patients in the normal range (Figure 1-10).  These data suggest that the ankle-brachial index 
does not have a monotonic relationship with cardiovascular risk, but rather a U-shaped 
relationship where patients with either an abnormally low or an abnormally high ABI have an 
elevated cardiovascular risk.  Data from the Cardiovascular Health Study,24 the Health ABC 
Study,25 and the Multi-Ethnic Study of Atherosclerosis26 have confirmed the likely U-shaped 
association between ABI and cardiovascular risk. 
i Reprinted with permission from Resnick et al Circulation 2004; 109: 733-739 
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 The physiological mechanism resulting in a high ABI is usually assumed to be medial arterial 
calcification (MAC) in the lower extremities.  Calcification of a lower extremity artery results in 
a falsely high reading of the ankle pressure due to stiffness in the arterial wall.  In extreme cases, 
this results in a condition known as a “non-compressible” artery in which the ankle pressure 
cannot be obliterated.  Most studies have shown that patients with non-compressible arteries 
have similar cardiovascular risk to those with very low ABI (Figure 1-11).  Notably, the 
prevalence of high ABI and non-compressible arteries is significantly higher in diabetic patients 
than the general population.117 
 
 
Figure 1-11. All-Cause and Cardiovascular Mortality Across the Spectrum of Ankle-
Brachial Index in the Health ABC Studyj 
j Reprinted with permission from Sutton-Tyrrell et al. Stroke 2008; 39: 863-869 
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 The role of peripheral arterial disease in this relationship is unclear.  Some patients with medial 
arterial calcification may have coexisting PAD, but such calcification also can occur in the 
absence of any atherosclerotic lesion in the arterial lumen.118  While several studies have shown 
elevated risk in patients with high ABI and/or non-compressible arteries, it is uncertain whether 
this excess risk is isolated to patients with underlying PAD or driven by some other disease 
process.  Notably, in a healthy community-based population, persons with high ABI had similar 
cardiovascular risk profiles and event rates as persons with normal ABI,119 and the 
aforementioned Health ABC data showed that the increased risk at the “high” end of ABI 
spectrum was far more pronounced in patients with non-compressible arteries than those with 
high ABI.25 Therefore, the use of high ABI as a marker of cardiovascular risk is still somewhat 
controversial. 
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 1.3.3 Measurement of ABI 
The most common technique for assessment of the ankle and arm blood pressure involves a 
continuous wave Doppler system, first reported by Yao et al in 1969.109 The protocol for 
measuring ankle-brachial index using Doppler ultrasound has been refined over several decades, 
but remains generally consistent across the cohort studies referenced above (Strong Heart Study, 
ARIC, CHS, MESA, and Health ABC).  The full Ultrasound Research Laboratory protocol for 
measuring Doppler ABI in the independent data collection project (see Appendix A) was 
developed based on the techniques established in these cohort studies. 
 
The ankle-brachial index can also be recorded with an oscillometric device (such as the Colin 
VP-1000 pulse waveform analyzer) that allows simultaneous blood pressure measurements at the 
right and left brachial and posterior tibial arteries.  Testing the reliablity and reproducibility of 
ABI measures from this device is a principal aim of the independent data collection project in 
this dissertation; the reliability of similar devices has been documented in a few previous studies 
and has displayed reasonable agreement with Doppler measurements (a detailed description of 
these studies can be found in Section 1.3.4).  The full Ultrasound Research Laboratory protocol 
used for the VP-1000 in the independent data collection project is included in Appendix B.   
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 1.3.4 Existing Studies of Oscillometric ABI vs. Doppler ABI 
Verberk et al published a 2012 meta-analysis120 which pooled the results of eighteen studies 
(N=3290) comparing oscillometric ABI measurements to the Doppler method and found an 
average difference of 0.020 ± 0.018, indicating that oscillometric ABI tended to be higher than 
Doppler, although this difference was not statistically significant (p=0.28).  The meta-analysis 
also reported a pooled linear correlation coefficient of 0.71 between Doppler ABI and 
oscillometric ABI.  It should be noted that there was substantial heterogeneity between studies 
included in the meta-analysis; possible explanations include the use of different oscillometric 
devices, variation between study protocols, and differences in study populations. 
 
Among the eighteen studies included in the meta-analysis mentioned above, eleven different 
oscillometric devices were used, and only two studies included in the pooled results used the 
Colin VP-1000 device available in the Ultrasound Research Laboratory.  Two other studies have 
compared ankle blood pressures measured with the Colin to those measured with a Doppler 
probe, but these studies were not included in the meta-analysis due to lack of ABI data.  The four 
studies comparing Colin and Doppler are summarized briefly here. 
 
Cortez-Cooper et al (2003)121 compared ankle blood pressure measurements taken with the Colin 
to those taken with Doppler in 52 healthy participants. This study showed strong linear 
correlation between ankle pressures (r=0.95) taken with Colin versus Doppler.  Ankle pressures 
measured with Doppler were slightly higher (mean difference = 2.2 mm Hg) than Colin ankle 
pressures, but this difference was not statistically significant.  Following this study, Nukumizu et 
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 al (2007)122 compared Doppler ankle pressures to Colin ankle pressures in 168 participants from 
a vascular clinic, all of whom had angiographically confirmed PAD (n=146) or abdominal aortic 
aneurysm (n=22).  The Colin ankle pressures were slightly higher than Doppler ankle pressures, 
on average, but with no significant evidence of a difference.  Nukumizu et al did not report a 
mean difference, but instead reported the ratios of Colin pressure divided by Doppler pressure 
for each participant, noting that 135 of 168 (80%) participants had a Colin ankle pressure within 
10 percent of their Doppler ankle pressure. 
 
In the largest study comparing Colin ABI measurements to Doppler ABI measurements, Pan et 
al (2007)123 performed a population-based study analyzing data from 946 participants in several 
rural villages south of Shanghai.  The Doppler ABI measurements were slightly higher than the 
Colin ABI measurements (mean difference=0.03).  Richart et al (2009)124 also found that 
Doppler ABI tended to be slightly greater than Colin ABI in a study of 105 participants but the 
difference was not statistically significant.  The results from the four prior studies comparing 
Colin and Doppler ankle pressures and/or ABI can be synthesized into the following statements:  
 
1) The Colin has displayed reasonable agreement with Doppler in participants with normal ABI.  
2) The Colin may be less accurate for patients with extreme values of ABI (both low and high); 
in particular, it may provide falsely normal values for patients with very low values of ABI. 
3) It is difficult to establish a directional relationship between Colin and Doppler measurements; 
three of the four studies suggest that the Doppler tends to report slightly higher ankle 
pressures and/or ABI than the Colin, but this could be accounted for by differences in study 
populations and protocol. 
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 1.3.5 Clinical Significance and Guidelines  
As detailed above, the ankle-brachial index provides valuable information about cardiovascular 
risk at both ends of the spectrum.  Patients with either a low ABI or a high ABI are at increased 
cardiovascular risk and should be treated accordingly; as such, the ABI should be considered an 
effective, noninvasive screening tool that can be implemented at low cost: the PARTNERS 
program demonstrated that ABI technique can be easily performed by both nurses and physicians 
in the primary care setting.28  Guidelines established by the American Heart Association125 call 
for a screening ABI in high-risk patients meeting one or more of the following criteria: 
 
 Individuals with exertional leg symptoms 
 Individuals with nonhealing wounds 
 Individuals who are 70 years and older 
 Individuals who are 50 years and older with a history of smoking or diabetes. 
 
Congruent with the last recommendation in the list above, the American Diabetes Association 
recommends that a screening ABI be performed in all diabetic individuals over 50 years of age, 
regardless of symptoms.  If the patient has a normal ABI (0.91-1.30), it is recommended that the 
test be repeated within five years.  However, if a patient presents with claudication symptoms, a 
screening ABI should be performed immediately regardless of time since the last test. 
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 1.4 SUMMARY 
The proposed research will produce three unique manuscripts with the principal focus of 
improving our knowledge of peripheral arterial disease.  This introduction gives an overview of 
the prevalence of PAD, the effects of established cardiovascular risk factors on PAD risk, 
pertinent background information on selected novel risk factors that may explain part of the 
additional risk for PAD in type 2 diabetes, and a history of the principal diagnostic test for PAD 
and its utility.  The specific aims of the three manuscripts are outlined on the following page. 
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 2.0  SPECIFIC AIMS 
This dissertation is composed of three manuscripts, each pertaining to peripheral arterial disease.   
 
Specific Aim for Manuscript 1:  
Test for difference in PAD incidence between two randomly assigned glycemic control strategies 
in a large cohort of T2DM patients free of PAD at study entry.  This paper will inform 
physicians of the best treatment practice for diabetes patients at high risk for developing PAD.   
 
Specific Aim for Manuscript 2:  
Perform longitudinal analysis of the relationship(s) between established CVD risk factors, novel 
CVD risk factors, and the incidence of PAD.  This paper could improve our knowledge of the 
pathophysiology of PAD in diabetes as well as provide insights into the effects of different 
glycemic control medications on the progression of atherosclerosis in this population. 
 
Specific Aim for Manuscript 3: 
Evaluate the reliability of ankle-brachial index measurements obtained using the Colin VP-1000 
pulse waveform analyzer versus the traditional Doppler ultrasound method of measuring ABI.  
This project will provide useful quality-control data for the Ultrasound Research Laboratory, 
which uses the VP-1000 extensively in research studies, and its findings also may be generalized 
to other research settings.  
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 3.0  MANUSCRIPT 1: FAVORABLE EFFECTS OF INSULIN SENSITIZERS 
PERTINENT TO PERIPHERAL ARTERIAL DISEASE IN TYPE 2 DIABETES: 
RESULTS FROM THE BYPASS ANGIOPLASTY REVASCULARIZATION 
INVESTIGATION 2 DIABETES (BARI 2D) TRIAL 
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 3.1 ABSTRACT 
(Oral Presentation at the American Diabetes Association 2012 Scientific Sessions) 
Objective: The aim of this manuscript was to report the risk of incident peripheral arterial 
disease in a large randomized clinical trial that enrolled participants with stable coronary artery 
disease (CAD) and type 2 diabetes and compare the risk between assigned treatment arms.   
Research Design and Methods:  The Bypass Angioplasty Revascularization Investigation 2 
Diabetes (BARI 2D) trial randomly assigned participants to insulin-sensitization (IS) therapy vs. 
insulin-providing (IP) therapy for glycemic control.  Results showed similar five-year mortality 
in the two glycemic treatment arms.  In secondary analyses reported here, we examine the effects 
of treatment assignment on the incidence of peripheral arterial disease (PAD).  1479 BARI 2D 
participants with normal ABI (0.91-1.30) were eligible for analysis.  The following PAD-related 
outcomes are evaluated in this manuscript: new low ABI ≤0.9, a lower extremity 
revascularization, lower extremity amputation, and a composite of the three outcomes.   
Results: During an average 4.6 years of follow-up, 303 participants experienced one or more of 
the outcomes listed above.  Incidence of the composite outcome was significantly lower among 
participants assigned to IS therapy than those assigned to IP therapy (16.9% vs. 24.1%; 
P<0.001).  The difference was significant in time-to-event analysis (HR=0.66, 95% CI [0.51, 
0.83], P<0.001) and remained significant after adjustment for in-trial HbA1c (HR=0.76, 95% CI 
[0.59, 0.96], P=0.02). 
Conclusions: In participants with type 2 diabetes mellitus that are free from PAD, a glycemic 
control strategy of insulin sensitization may be the preferred therapeutic strategy to reduce the 
incidence of PAD and subsequent outcomes. 
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 3.2 INTRODUCTION 
Peripheral arterial disease (PAD) is an atherosclerotic condition characterized by chronic 
occlusion of the arteries in the lower extremities.  Prevalence estimates suggest that at least 5 
million Americans have PAD.14,15  The presence of PAD is a marker of generalized systemic 
atherosclerosis and is associated with cardiovascular morbidity and mortality.22,23,24,25,26,27 
 
PAD is especially common in patients with type 2 diabetes mellitus.41  PAD progresses more 
rapidly80 and leads to worse outcomes84 in type 2 diabetes patients than nondiabetic patients.  
Type 2 diabetes patients with PAD have a high risk of functional impairment,81 mobility loss,19   
amputation,82 and cardiovascular mortality.85 High levels of glycosylated hemoglobin (HbA1c) is 
independently associated with increased risk of PAD in type 2 diabetes, suggesting that poor 
glycemic control may be a risk factor for PAD.90,91,92,126   Prior reviews have speculated that 
treatment with insulin sensitizers may reduce the risk of PAD in type 2 diabetes patients.99,100,101  
However, this has never been demonstrated in a randomized controlled trial. 
 
The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial provides an 
opportunity to compare the effects of an insulin-sensitizing glycemic control strategy to an 
insulin-providing strategy on the incidence of PAD in a cohort of participants with type 2 
diabetes and documented stable coronary artery disease.  We have previously demonstrated that 
mortality and incidence of major cardiovascular events was comparable in the glycemic control 
arms.127   In this report, we present the results of secondary analyses undertaken to examine the 
association between glycemic treatment assignment and the incidence of PAD. 
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 3.3 METHODS 
BARI 2D Trial 
A detailed explanation of the BARI 2D trial has been published elsewhere.128,129  The primary 
aim of the BARI 2D trial was to determine the optimal treatment for participants with type 2 
diabetes mellitus and documented stable coronary artery disease (CAD).  The BARI 2D trial 
utilized a 2x2 factorial design in which participants were assigned at random to initial elective 
revascularization with intensive medical therapy (REV) versus intensive medical therapy alone 
(MED) while simultaneously assigned at random to an insulin sensitizing (IS) strategy versus an 
insulin providing (IP) strategy of glycemic control.  All participants were treated medically to 
achieve targets of HbA1c < 7.0%, LDL cholesterol < 100 mg/dL, and blood pressure ≤ 130/80 
mm Hg.  All participants received counseling regarding smoking cessation, weight loss, and 
regular exercise. 
 
BARI 2D included 49 clinical sites throughout North America, South America, and Europe and 
was coordinated at the University of Pittsburgh.  The local institutional review boards approved 
trial protocol and all participants provided informed consent.  Recruitment began in 2001 and 
continued until 2005; treatment continued until the 6-year visit or the last annual visit before 
December 1, 2008.  The overall study cohort for BARI 2D consisted of 2368 participants.  The 
primary endpoint for BARI 2D was death from any cause, and the principal secondary endpoint 
was a composite of death, myocardial infarction, or stroke.  Results for each of these have been 
published elsewhere.127 This manuscript reports the results of a post hoc analysis to examine 
peripheral arterial disease and related outcomes. 
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 Glycemic Control Strategies 
All BARI 2D participants were treated with a target HbA1c < 7.0%.  Participants assigned to IP 
therapy could be treated with sulfonylureas, repaglinide, nateglinide, or insulin itself.  
Participants assigned to IS therapy could be treated with thiazolidinedones (glitazones) and/or 
metformin.  Alpha-glucosidase inhibitors could be used with either treatment assignment.  The 
trial was not designed to compare specific drugs, but rather to compare the 2 mechanistically 
different treatment strategies.  A detailed description of the BARI 2D glycemic control protocol 
can be found in Magee et al.130  Participants with HbA1c>8.0% while taking the assigned 
treatment were permitted to receive the glucose-lowering drugs from the opposite treatment arm 
to bring HbA1c within the range 7.0% to 8.0%.  Approximately 30% of participants assigned to 
IS treatment also required medications from the IP arm, while 10% of participants assigned to IP 
treatment required medications from the IS arm.  Nearly 90% of participants in both the insulin-
sensitization group and the insulin-provision group were taking their assigned medications at 
three years.127 
 
Diagnosis of Peripheral Arterial Disease 
The following lower-extremity outcomes were analyzed: recorded decrease in ankle-brachial 
index (ABI) to abnormal level (ABI ≤ 0.9), lower extremity revascularization, and lower 
extremity amputation.  This manuscript reports incidence of each individual outcome as well 
incidence of a composite PAD outcome including participants with any one of the individual 
outcomes.  Only participants with a normal ABI (0.91-1.30) at study entry were eligible for the 
primary analysis in this manuscript; the cutoff values for low, normal, and high ABI are chosen 
in accordance with values published in an ADA consensus statement on peripheral arterial 
43 
 disease in diabetes.  In secondary analysis, we report the incidence of lower extremity 
revascularization and amputation among participants with low ABI (<0.9) at study entry.   
 
We have previously reported the baseline prevalence and predictors of abnormal ABI in the 
BARI 2D trial.131  Participants with abnormal ABI at study entry were excluded from the 
primary analysis in this manuscript because i) participants with low ABI at study entry were 
deemed as already having PAD and ii) participants with high ABI and/or non-compressible 
arteries are likely to have arterial calcifications that would make it difficult to diagnose PAD 
using the ankle-brachial index.  Participants with a history of lower extremity revascularization 
or lower extremity amputation were also excluded from the primary analysis because of the 
likelihood that these participants already suffered from PAD.  The algorithm for determining 
PAD status in this manuscript is as follows: 
 
Each participant’s ABI was measured at study entry and annually thereafter.  All ABI 
measurements were taken by certified technicians using a Doppler probe.  Participants were 
asked to rest in a supine position for 5 minutes, after which the technician recorded the systolic 
blood pressure of the brachial artery of both arms and the posterior tibial artery of both ankles.  
The higher of the two brachial pressures was used to calculate ABI for each leg, and participants 
were classified according to their lowest ABI.  Participants with normal ABI (0.91-1.30) at study 
entry were defined as incident cases of PAD if they had an ABI≤0.9 during follow-up with a 
decrease of at least 0.1 from their baseline measurement. 
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 Participants who had a lower extremity revascularization or amputation during follow-up were 
included in the composite PAD outcome, even in the absence of a recorded low ABI.  We 
acknowledge that lower extremity revascularization and amputation may be performed for 
reasons other than atherosclerotic PAD, so the incidence of each outcome is reported in this 
manuscript as well as the composite PAD outcome to allow reader assessment of practical 
implications.  Intermittent claudication was not considered as an outcome because BARI 2D did 
not employ a validated claudication questionnaire. 
 
Statistical Methods 
The primary comparative analyses were performed according to the intention-to-treat principle.  
In addition, we performed “per-protocol analyses” that include only participants who remained 
on assigned treatment without any use of medications from the opposing treatment arm after the 
initial 6 months of the trial when study treatments were to be implemented and adjusted.  
Descriptive statistics include means ± SDs and proportions; medians and interquartile ranges are 
presented for highly skewed data.  Variables were compared between the two randomized 
glycemic control strategies (IS vs. IP) using t-tests, Wilcoxon tests, and chi-squared tests for 
continuous, skewed continuous, and categorical data, respectively.   
 
Kaplan-Meier estimates of the 5-year event rates were calculated for outcomes of interest and 
log-rank tests were used to compare the incidence of each PAD outcome by assigned glycemic 
control strategy for patients with normal ABI at baseline, as described above.  Time-to-event for 
each lower extremity outcome was defined as time from date of randomization to the event (new 
low ankle-brachial index, lower extremity revascularization, or lower extremity amputation); for 
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 the composite outcome, time-to-event was defined as time from date of randomization to the first 
event.  In the absence of an event, participants were censored at their last full-protocol follow-up 
visit.  We performed a second analysis to compare incidence of lower extremity 
revascularization and amputation in patients with low ABI at baseline to assess the incidence of 
severe outcomes in these patients.  We also calculated Kaplan-Meier event rates for the 
composite PAD outcome stratified by insulin use at study entry to see if the effects of assigned 
glycemic control strategy were consistent regardless of previous use of insulin therapy. 
 
Cox proportional-hazards models were used to estimate hazard ratios and associated 95% 
confidence intervals for IS strategy with IP as reference group.  Time-to-event was defined in the 
same fashion described above.  A second model was constructed with in-trial HbA1c included as 
a time-varying covariate, updated at the time of each new ABI measurement, to determine 
whether potential differences between IS and IP strategy were attenuated by adjustment for 
glycemic control.  The effects of assigned cardiovascular treatment strategy and the interaction 
between the assigned glycemic control strategy and cardiovascular treatment strategy were also 
tested.  P-values less than 0.05 were considered statistically significant; no adjustment was made 
for multiple comparisons. 
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 3.4 RESULTS 
The BARI 2D study population consisted of 2368 participants with type 2 diabetes mellitus and 
stable CAD.  Only participants with normal ABI at study entry and no history of PAD were 
selected for this paper’s primary analysis.  889 participants were excluded due to history of PAD, 
missing baseline ABI, or abnormal baseline ABI, leaving 1479 BARI 2D participants eligible for 
this analysis (Figure 3-1).  The participants excluded from this analysis were generally older, 
heavier, more likely to be smokers, had higher systolic blood pressure, higher pulse pressure, a 
longer duration of diabetes, and were more likely to have renal dysfunction at study entry than 
those included in this analysis (data not shown).  Since many of the participants excluded from 
this analysis had a history of PAD, this is consistent with expectations. 
 
Participants included in the intention-to-treat analysis were age 61.9 ± 8.0 years old, 72% male, 
and 15% African-American.  The distribution of baseline lipid values, blood pressure, glycemic 
control, and markers of renal function were similar between the assigned glycemic treatment 
groups (Table 3-1).  The mean ABI at study entry was 1.10 in the IS group and 1.09 in the IP 
group (p=0.23).  There were no significant differences in major baseline demographic or clinical 
characteristics between the assigned glycemic treatment groups. 
 
Incidence of the composite PAD outcome was significantly lower in the IS arm than in the IP 
arm (16.9% vs. 24.1%, p<0.001, event rates for all intention-to-treat comparisons in Table 3-2).  
On the time-to-event curve, the difference becomes noticeable after three years and increases 
during longer follow-up (Figure 3-2).  Examining each clinical outcome separately, participants 
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 assigned to IS therapy had a significantly lower rate of low ABI (16.5% vs. 22.7%, p<0.001) and 
amputation (0.1% vs. 1.6%, p=0.002) and a moderately lower rate of lower extremity 
revascularization (1.1% vs. 2.6%, p=0.07) than those assigned to IP therapy.  Among participants 
with low ABI at baseline, we observed no significant difference between the IS arm and IP arm 
in risk of lower extremity revascularization (7.7% vs. 6.7%, p=0.68) or lower extremity 
amputation (3.4% vs. 7.2%, p=0.08).   
 
The lower risk of PAD and related outcomes in participants assigned to IS therapy was also 
significant in time-to-event analyses using Cox models (HR for IS vs. IP therapy for composite 
outcome=0.66, 95% CI [0.51, 0.83], p<0.001, Table 3-3).  The effects of glycemic control 
strategy were partially attenuated by adjustment for in-trial HbA1c; however, even with 
adjustment for in-trial HbA1c, there was a significantly lower risk of PAD in participants 
assigned to IS therapy (adjusted HR for IS vs. IP therapy for composite outcome=0.76, 95% CI 
[0.59, 0.96], p=0.02).  None of the PAD outcomes were associated with assigned cardiovascular 
treatment strategy, and no interactions between glycemic control and cardiovascular treatment 
strategies were statistically significant (p>0.10 for all). 
 
Among participants in the per protocol analysis, there were significant baseline differences 
between the glycemic control arms in average duration of diabetes, proportion using insulin at 
study entry, and HbA1c (Table 3-4) but not in other risk factors such as age, smoking, race or 
baseline ABI.  As in intention-to-treat analyses, the results generally favor IS therapy for each 
outcome (incidence of composite outcome 12.4% vs. 26.0%, p<0.001; event rates for all per-
protocol comparisons shown in Table 3-5).  The effects of IS therapy are also significant in per-
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 protocol analyses when using time-to-event analyses (HR for IS vs. IP therapy for composite 
outcome= 0.44, 95% CI [0.31, 0.62], p<0.001, Table 3-6).   As in the intention-to-treat analyses, 
the effect of glycemic control strategy is partially attenuated by adjustment for in-trial HbA1c in 
the per-protocol analysis, but still significant (adjusted HR for IS vs. IP therapy for composite 
outcome= 0.54, 95% CI [0.37, 0.79], p=0.002).   
 
Insulin treatment at study entry was associated with greater risk of the composite PAD outcome 
(patients on insulin: 26.3% vs. patients not on insulin: 18.5%, p=0.01).  There was a significant 
difference in risk for the composite PAD outcome between the glycemic control arms regardless 
of whether participants were receiving insulin at study entry (Figure 3-3 and Figure 3-4).  The 
incidence of PAD was lower in the IS arm among participants receiving insulin at study entry 
(IS: 20.7% vs. IP: 31.9%, p=0.01) and also those not receiving insulin at study entry (IS: 15.6% 
vs. IP: 21.3%, p=0.01).  The difference in PAD incidence between the IS arm and the IP arm 
tended to emerge earlier for participants on insulin at study entry. 
49 
 3.5 DISCUSSION 
In a large cohort of participants with stable CAD and type 2 diabetes mellitus, participants 
assigned to insulin sensitizing therapy experienced significantly fewer cases of incident PAD 
than participants assigned to insulin providing therapy over an average of 4.6 years of clinical 
follow-up.  The difference in PAD risk between the glycemic control arms was significant 
regardless of assigned cardiovascular treatment strategy and consistent in both intention-to-treat 
analyses and per-protocol analyses. The results also favored insulin sensitizing therapy for 
patients receiving insulin at study entry as well as those not receiving insulin at study entry.  This 
is the first randomized controlled trial to demonstrate that treatment with insulin sensitizing 
agents reduces the risk of incident peripheral arterial disease in participants with type 2 diabetes 
mellitus. 
 
The reduction in risk of amputation and/or revascularization with IS therapy was not as 
pronounced for patients with low ABI at baseline, although the incidence of each outcome was 
still lower for patients assigned to IS therapy than for patients assigned to IP therapy.  This could 
be explained in two ways.  First, perhaps IS therapy does have a benefit for these patients, but 
there was insufficient sample size to detect an effect in the subgroup with low ABI at study 
entry.  Alternatively, it’s possible that the benefit of IS therapy on peripheral outcomes is 
lessened in patients with existing PAD because the disease in the lower extremities has advanced 
beyond “prevention” of the atherosclerotic process in this vascular bed. 
 
The only previous study to demonstrate a similar result is the PROactive trial, which found that 
treatment with pioglitazone versus placebo resulted in a moderate decrease in the rate of leg 
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 revascularizations and amputations among participants free from PAD at study entry.83  Notably, 
the BARI 2D results demonstrate an even stronger benefit of insulin sensitizing therapy in this 
population.  This may be explained by the shorter follow-up time in PROactive (three years) than 
BARI 2D (five years), since the BARI 2D results showed that the treatment benefit of IS therapy 
began to emerge around three years and progressively increased thereafter.  It could also be a 
result of moderate differences in treatment protocol; PROactive randomly assigned patients to 
pioglitazone or placebo in the setting of continued additional diabetes therapy, whereas BARI 2D 
assigned patients to insulin sensitizing strategy or insulin providing strategy. 
 
One potential mechanism through which IS treatment may have reduced the risk of PAD 
incidence in BARI 2D is better glycemic control; we have previously reported that participants 
assigned to IS had lower HbA1c than participants assigned to IP during BARI 2D follow-up.98  
However, the treatment difference reported here was significant after adjustment for in-trial 
HbA1c, suggesting that IS therapy conferred a benefit beyond better glycemic control. 
 
Furthermore, previous trials of intensive glucose-lowering therapy have not demonstrated a 
consistent reduction in macrovascular outcomes.  The Veterans Affairs Diabetes Trial (VADT), 
the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial and the Action in 
Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation 
(ADVANCE) trial all failed to demonstrate that intensive glucose-lowering therapy reduced the 
risk of macrovascular outcomes.94,95,96  With that in mind, the BARI 2D results are particularly 
encouraging because the decreased risk of PAD in participants assigned to insulin sensitizing 
therapy was significant even while adjusting for in-trial glycemic control, suggesting that 
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 improvements in macrovascular outcomes may be achieved by changing the mechanistic 
approach rather than targeting a lower HbA1c. 
 
A second plausible mechanism of the reduced PAD risk with IS therapy may be the anti-
inflammatory effects of thiazolinediones used in the BARI 2D trial, which may retard 
atherosclerosis development and progression.132,133   We have previously reported that the IS 
strategy led to changes in biomarker profiles indicative of a profibrinolytic, antithrombotic, and 
anti-inflammatory state. 98 This could contribute to the lower incidence of PAD in the IS group.  
While thiazolinediones have been shown to induce and maintain the regression of carotid intima-
media thickness in participants with type 2 diabetes,134 to our knowledge no previous study has 
reported an effect on peripheral arterial disease.  However, because the BARI 2D trial was 
designed to examine mechanistically different treatment strategies rather than individual drugs, 
we cannot say for certain whether thiazolinediones alone were responsible for the reduction in 
PAD risk. 
 
It is also plausible that the observed results reflect a harmful effect of IP therapy rather than a 
protective benefit of IS therapy.  Hyperinsulinemia has long been a known risk factor for 
atherosclerosis, although the causality of the relationship is controversial, and the mechanism is 
unclear.  One study suggests that hyperinsulinemia may promote atherosclerosis by promoting 
macrophage foam cell accumulation.135  However, this is not clearly established; further research 
is needed to determine the potential atherogenic effects of insulin. 
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 To date, no pharmacologic therapies have proven to reduce the risk of incident PAD in type 2 
diabetes patients.  The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study 
has reported lower amputation rates in patients assigned to treatment with fenofibrate versus 
placebo; however, PAD status at study entry was not reported for the FIELD results, so we are 
uncertain whether these findings extend to incident cases of PAD.136  For patients with PAD, 
current ACC/AHA guidelines recommend aggressive management of atherosclerotic risk factors 
to reduce future cardiovascular events.137  Exercise conditioning138 and smoking cessation139 
have proven beneficial effects for those with PAD, but these are generally recommended for all 
type 2 diabetes patients regardless of their effects on PAD risk.  Notably, while all participants in 
BARI 2D received intensive medical therapy, counseling regarding smoking cessation, and 
regular exercise, treatment with insulin sensitizing agents still resulted in fewer cases of incident 
PAD than treatment with insulin providing agents. 
 
One potential limitation of this research is the composition of the BARI 2D population, which 
was restricted to patients with documented coronary artery disease suitable for elective 
revascularization and type 2 diabetes mellitus.  Given that both of these conditions are 
independently associated with peripheral arterial disease, the BARI 2D population is at very high 
risk for PAD, and therefore, the findings from this research may not extend to those at lower risk.  
Further study will be needed to determine if insulin sensitizing medications offer the same 
benefit to lower-risk patients.  Additional limitations include the fact that individual drugs cannot 
be evaluated because of the trial design, which assigned patients to a mechanistic treatment 
strategy rather than a specific drug, and the lack of a standardized claudication questionnaire, 
which might have resulted in the diagnosis of a few more PAD cases during follow-up. 
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 3.6 CONCLUSION 
In summary, we have reported that an insulin sensitizing strategy for glycemic control resulted in 
fewer incident PAD cases, lower extremity revascularizations, and lower extremity amputations 
than treatment with insulin providing agents in type 2 diabetes patients.  The difference between 
glycemic treatment arms remained significant with adjustment for in-trial HbA1c, suggesting 
that insulin sensitizers confer a benefit independent of glycemic control.  Our results suggest that 
treatment of type 2 diabetes patients with insulin sensitizers might reduce the morbidity and 
treatment cost of PAD in this population. 
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 3.7 TABLES AND FIGURES 
 
 
 Assigned Glycemic 
Control Strategy 
 
 IS 
(N=735) 
IP 
(N=744) 
P-Value 
Age at Study Entry, Years 61.8, 8.9 62.0, 8.7 0.68 
Sex (Male), % 71.7 71.9 0.92 
Race (Black), % 16.2 14.5 0.37 
BMI, kg/m2 31.6, 5.9 31.4, 5.6 0.48 
Current Smoker, % 11.7 11.4 0.87 
    
Cholesterol, mg/dl 166.7, 41.0 170.2, 39.6 0.11 
LDL, mg/dl 94.4, 33.0 96.7, 31.8 0.18 
HDL, mg/dl 37.6, 9.6 38.2, 10.1 0.25 
Triglycerides*, mg/dl 146 (99-217) 152 (108-220) 0.37 
Systolic BP, mm Hg 130.9, 18.7 130.0, 19.1 0.39 
Diastolic BP, mm Hg 75.0, 11.0 74.3, 10.6 0.26 
Pulse Pressure, mm Hg 55.9, 15.1 55.7, 14.7 0.78 
CRP*, (ug/mL) 2.1 (1.0-5.7) 2.2 (1.0-5.2) 0.72 
Number of Vessels >50% Stenosis    
      0/1 37.6 32.4 0.07 
      2 33.2 38.7  
      3 29.1 28.8  
Proximal LAD > 50% Stenosis 12.1 15.2 0.08 
Left Ventricular Ejection Fraction 57.6, 10.7 58.1, 10.7 0.42 
Baseline ABI 1.10, 0.10 1.09, 0.11 0.23 
    
Duration of DM, Years 9.4, 8.0 9.9, 8.2 0.25 
HbA1c, % (mmol/mol) 7.6 (60), 1.6 7.7 (61), 1.6 0.10 
Diabetic Peripheral Neuropathy* 50.8% 49.2% 0.75 
eGFR** 
77.6 (63.8-
91.5) 
76.6 (64.2-
91.5) 0.93 
eGFR<60, % 19.8 18.8 0.62 
ACR*, mg/g 10.7 (4.8-42.4) 10.8 (5.2-34.6) 0.80 
Albuminuria, %    
     No Albuminuria (ACR<30) 70.0 72.8 0.49 
Table 3-1. Baseline Characteristics of BARI 2D Patients with Normal ABI at 
Study Entry (N=1479), by Assigned Glycemic Control Strategy  
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      Microalbuminuria (30<ACR<300) 22.6 20.1  
     Macroalbuminuria (ACR>300) 7.4 7.1  
    
Diabetes Medications At Study Entry    
   Insulin, % 25.6 25.7 0.97 
   Sulfonylurea, % 53.4 53.4 0.99 
   Metformin, % 55.9 55.8 0.98 
   Thiazolidinedones, % 20.6 17.2 0.10 
IS =Insulin Sensitizing Assignment; IP = Insulin Providing Assignment; BMI = body mass 
index; LDL = low-density lipoprotein; HDL = high-density lipoprotein; BP = blood pressure; 
CRP = C-reactive protein; LAD = left anterior descending; ABI = ankle-brachial index; DM = 
diabetes mellitus; HbA1c= glycosylated hemoglobin; eGFR = estimated glomerular filtration 
rate; ACR = albumin/creatinine ratio 
*Diabetic peripheral neuropathy assessed using Michigan Neuropathy Screening Instrument 
(clinical MNSI score ≥ 2) 
**Triglycerides, eGFR, ACR, and CRP presented as median (Q1-Q3) because of their skewed 
distributions
Table 3-1 Continued 
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Table 3-2. Cumulative Incidence of Lower Extremity Outcomes, by Assigned Glycemic 
Control Strategy, Intention-To-Treat Analysis 
 Patients with Normal ABI 
at Study Entry (N=1479) 
 
 IS 
(N=735) 
IP 
(N=744) 
P-Value 
Peripheral Arterial Disease* 124 
(16.9%) 
179 
(24.1%) 
<.001 
Incident Low ABI 121 
(16.5%) 
169 
(22.7%) 
0.001 
Lower Extremity Revascularization 8 
(1.1%) 
17 
(2.6%) 
0.07 
Lower Extremity Amputation 1 
(0.1%) 
12 
(1.6%) 
0.002 
 Patients with Low ABI at 
Study Entry (N=430) 
 
 IS 
(N=207) 
IP 
(N=223) 
P-Value 
Lower Extremity Revascularization 14 
(6.7%) 
17 
(7.7%) 
0.69 
Lower Extremity Amputation 7 
(3.4%) 
16 
(7.2%) 
0.08 
Revascularization and/or 
Amputation 
19 
(9.2%) 
25 
(11.2%) 
0.48 
IS =Insulin Sensitizing Assignment; IP = Insulin Providing Assignment 
*Patients are classified as an incident case of peripheral arterial disease if any of the following 
occur: i) ABI < 0.9 with a decrease of 0.1 from baseline, ii) lower extremity revascularization, 
iii) lower extremity amputation 
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 Table 3-3. Effects of Assigned Glycemic Control Strategy on Lower Extremity Outcomes 
(N=1479) 
  Unadjusted Adjusted for in-trial HbA1c 
Outcome # Events HR 95% CI P-Value HR 95% CI P-Value 
Peripheral Arterial 
Disease 
303 0.66 0.51, 0.83 <.001 0.76 0.59, 0.96 0.02 
Incident Low ABI 290 0.68 0.54, 0.85 0.001 0.73 0.57, 0.93 0.002 
Lower Extremity 
Revascularization 
25 0.47 0.20, 1.09 0.08 0.58 0.24, 1.37 0.22 
Lower Extremity 
Amputation 
13 0.08 0.01, 0.63 0.02 0.12 0.02, 0.91 0.04 
HR = Hazard Ratio; 95% CI = 95% confidence interval 
*Hazard Ratios are for IS arm vs. IP arm (reference group) 
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 Table 3-4. Baseline Characteristics of Participants in Per Protocol Analysis (N=942) 
 IP 
(N=643) 
IS 
(N=299) 
P-Value 
Age at study entry, mean, sd 61.8, 8.7 62.3, 9.2 0.4413 
Male, % 71.7 75.9 0.1738 
Black, % 14.5 12.4 0.3869 
BMI, mean, sd 31.4, 5.6 30.6, 5.2 0.0385 
Current Smoker, % 10.7 10 0.7395 
    Total cholesterol mg/dl, mean, sd 171.1, 39.4 164.6, 39.1 0.0211 
LDL mg/dl, mean, sd 97.3, 31.3 93.7, 31.7 0.1144 
HDL mg/dl, mean, sd 38.4, 10.2 37.2, 9.1 0.0648 
Triglyceride mg/dl, mean, sd 184.8, 154.6 171.1, 113.3 0.1283 
Systolic BP average, mean, sd 130.2, 19.1 130.3, 19.4 0.9599 
Diastolic BP average, mean, sd 74.7, 10.7 76.2, 10.4 0.0436 
    Duration of DM, mean, sd 10.3, 8.2 6.6, 6.7 <.0001 
On insulin at study entry, % 28.1 5.0 <.0001 
HbA1c %, mean, sd 7.8, 1.6 7.0, 1.3 <.0001 
    ACR mg/g, mean, sd 125.9, 468.5 38.4, 122.9 <.0001 
Albuminuria categories, %   
     No albuminuria 72 79.5 0.0022 
    Micro albuminuria 20.7 18.7 
     Macro albuminuria 7.3 1.8 
 
    ABI, mean, sd 1.09, 0.1 1.10, 0.1 0.2684 
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 Table 3-5. Cumulative Incidence of Lower Extremity Outcomes, by Glycemic Control 
Strategy, Per Protocol Analysis (N=942) 
 IS 
(N=299) 
IP 
(N=643) 
P-Value 
Peripheral Arterial Disease* 37  
(12.4%) 
167  
(26.0%) 
<.001 
Incident Low ABI 36  
(12.0%) 
158 
 (24.6%) 
<.001 
Lower Extremity Revascularization 3 
(1.0%) 
15 
(2.3%) 
0.16 
Lower Extremity Amputation 0 
(0.0%) 
12 
(1.9%) 
0.002 
*Patients are classified as an incident case of peripheral arterial disease if any of the following 
occur: i) ABI < 0.9 with a decrease of 0.1 from baseline, ii) lower extremity revascularization, 
iii) lower extremity amputation 
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 Table 3-6. Effects of Glycemic Control Strategy on Lower Extremity Outcomes, Per 
Protocol Analysis (N=942) 
  Unadjusted Adjusted for in-trial HbA1c 
Outcome # 
Events 
HR 95% CI P-Value HR 95% CI P-Value 
Peripheral 
Arterial Disease 
204 0.44 0.31, 0.62 <.001 0.54 0.37, 0.79 0.002 
Incident Low ABI 194 0.44 0.31, 0.63 <.001 0.54 0.37, 0.80 0.002 
Lower Extremity 
Revascularization 
18 0.43 0.12, 1.48 0.18 0.70 0.18, 2.63 0.59 
Lower Extremity 
Amputation 
12 ** ** ** ** ** ** 
HR = Hazard Ratio; 95% CI = 95% confidence interval 
*Hazard Ratios are for IS arm vs. IP arm (reference group) 
**Hazard Ratio cannot be estimated for amputation because, in per-protocol analysis, all 
amputation events occurred in IP arm and there are no amputation events in IS arm 
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Figure 3-1. Flowchart of Ankle-Brachial Index Measurements Available in All BARI 2D 
Patients (N=2368) 
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Figure 3-2. Cumulative Incidence of Peripheral Arterial Disease and Related Outcomes, by 
Assigned Glycemic Control Strategy 
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Figure 3-3. Cumulative Incidence of Peripheral Arterial Disease Among Patients Not On 
Insulin at Baseline, by Assigned Glycemic Control Strategy 
 
 
Figure 3-4. Cumulative Incidence of Peripheral Arterial Disease Among Patients On 
Insulin at Baseline, by Assigned Glycemic Control Strategy 
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 4.0  MANUSCRIPT 2: RISK FACTORS FOR PERIPHERAL ARTERIAL DISEASE 
IN TYPE 2 DIABETES: RESULTS FROM THE BYPASS ANGIOPLASTY 
REVASCULARIZATION INVESTIGATION 2 DIABETES (BARI 2D) TRIAL 
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 4.1 ABSTRACT 
(Oral Presentation at the American Heart Association 2012 Scientific Sessions) 
Objective: Define risk factors for the incidence of peripheral arterial disease (PAD) in a large 
cohort of type 2 diabetes mellitus (T2DM) patients, overall and within the context of two 
different assigned glycemic control strategies.   
Research Design and Methods:  The Bypass Angioplasty Revascularization Investigation 2 
Diabetes (BARI 2D) trial randomly assigned participants to insulin-sensitization (IS) therapy vs. 
insulin-providing (IP) therapy.  In these secondary analyses, we examine baseline risk factors for 
the incidence of lower extremity outcomes within the overall cohort and time-varying risk 
factors within each assigned treatment arm.  1479 BARI 2D participants with normal ABI (0.91-
1.30) were eligible for analysis.  Cox proportional-hazards models were used to define the 
association between each risk factor and incidence of lower extremity outcome. 
Results: Age, sex, race, and smoking were all significantly associated with lower extremity 
outcomes in the BARI 2D cohort.  Additional baseline risk factors included systolic blood 
pressure, pulse pressure, HbA1c, albumin-creatinine ratio, and C-reactive protein.  In stratified 
analyses of time-varying covariates, changes in lipids, systolic blood pressure, pulse pressure, 
albumin-creatinine ratio, and D-dimer were most predictive among IS patients, while HbA1c was 
most predictive among IP patients. 
Conclusions: In participants with type 2 diabetes mellitus that are free from PAD, traditional 
cardiovascular risk factors accounted for most predictive value of incident lower extremity 
outcomes.  Inflammatory biomarkers such as C-reactive protein, fibrinogen, and D-dimer also 
were associated with increased risk of lower extremity outcomes, but may have more predictive 
value in patients treated with insulin sensitizing medications.  
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 4.2 INTRODUCTION 
Peripheral arterial disease (PAD) is a critical manifestation of atherosclerosis, a chronic disease 
that is one of the leading causes of death and disability in the United States.1 Prevalence 
estimates of PAD have steadily risen over the past several decades, and recent epidemiological 
data suggests that approximately 8 million Americans likely have PAD.12,13,15 Patients with PAD 
have increased risk of functional limitation, physical disability, leg revascularization, and 
amputation.18,19,20  The presence of PAD is indicative of generalized systemic atherosclerosis and 
therefore associated with increased risk of all-cause mortality and cardiovascular 
mortality.22,23,24,25,26,27  
 
PAD is especially common among patients with type 2 diabetes mellitus (T2DM).  Patients with 
T2DM have an abnormal cluster of hyperglycemia, elevated free fatty acids, and insulin 
resistance that results in oxidative stress and endothelial dysfunction, key steps in the 
atherosclerotic process that could lead to PAD.140,141 NHANES data suggest that patients with 
T2DM have a threefold increased risk of PAD compared to the general population.14 PAD also 
tends to progress faster and lead to worse outcomes in T2DM patients than in nondiabetic 
patients.84 The American Diabetes Association has previously issued a consensus statement with 
guidelines for the diagnosis and management of PAD in patients with diabetes, in recognition of 
the common nature and severity of this problem.41 
 
In addition to the excess risk for patients with T2DM, previous studies have identified a number 
of risk factors for PAD including age, race, smoking, hypertension, and lipids.16,30,31,32,34  The 
direction of these relationships generally matches those between the same risk factors and 
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 coronary artery disease (CAD), although the magnitude of some relationships varies; for 
example, smoking carries a stronger relationship with PAD than it does with CAD.  There is also 
growing evidence that several biomarkers indicative of inflammation and/or coagulation such as 
C-reactive protein (CRP), D-dimer, and fibrinogen may be associated with increased PAD risk 
and/or worse outcomes in peripheral arterial disease.73,74,75,76,142,143,144,145  
 
In the context of developing atherosclerosis, CRP, fibrinogen, and D-dimer are indicative of 
distinct but related processes pertaining to inflammation, coagulation, and fibrinolysis.146  An 
uncontrolled coagulatory response to inflammation may lead to a situation in which coagulation 
and/or thrombosis contribute to disease; for example, thrombus formation on a ruptured 
atherosclerotic plaque is the pathologic basis of an acute thrombotic event.  Even before an acute 
event, elevated levels of these biomarkers are indicative of inflammatory and coagulatory 
cascades that may correspond with the development of atherosclerosis.  The acute fibrinolytic 
response to inflammation results in the release of tissue-type plasminogen activator (tPA) and 
plasminogen activator inhibitor-1 (PAI-1),54 which may also provide predictive value.  
 
Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial 
suggest that T2DM patients treated with an insulin sensitizing (IS) regimen experienced 
improvements in biomarker profiles not observed in those assigned to an insulin providing (IP) 
regimen.98 While this did not result in a reduction in all-cause mortality, patients assigned to the 
IS strategy experienced significantly lower incidence of PAD than those assigned to the IP 
strategy.147 Therefore, we sought to determine whether the relationship between these changing 
biomarker profiles and incidence of PAD is influenced by the assigned glycemic control strategy. 
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 All BARI 2D participants had clinically significant atherosclerosis in the coronary arteries at 
study entry; however, incidence of new PAD is still informative because it represents the 
advancement of generalized atherosclerosis.  Identifying risk factors for incident PAD in this 
population improve our understanding of how insulin sensitizing and insulin providing 
medications affect the progression of atherosclerosis.  There is little longitudinal data exploring 
how time-varying changes in these biomarkers are associated with new atherosclerosis, and few 
existing studies have explored these biomarkers as risk factors for incident PAD in a population 
of T2DM patients.  Therefore, our principal aim is to establish the associations between 
inflammatory biomarkers and incidence of PAD in T2DM patients; as a secondary aim, we aim 
to define risk factors for PAD incidence in the context of each of the BARI 2D glycemic control 
strategies.   
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 4.3 METHODS 
BARI 2D Trial 
The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial was 
designed to determine optimal treatment strategy for patients with stable coronary artery disease 
and type 2 diabetes mellitus.128  BARI 2D participants were randomly assigned via 2x2 factorial 
design to prompt coronary revascularization with intensive medical therapy (REV) versus 
intensive medical therapy alone (MED) and simultaneously randomly assigned to either an 
insulin sensitizing (IS) glycemic control strategy or an insulin providing (IP) strategy.  All 
participants were treated medically to achieve targets of HbA1c < 7.0%, LDL cholesterol < 100 
mg/dL, and blood pressure ≤ 130/80 mm Hg as well as given counseling for smoking cessation, 
weight loss, and exercise.  BARI 2D was coordinated at the University of Pittsburgh and 
included 49 clinical sites throughout North America, South America, and Europe.  Recruitment 
began in 2001 and continued until 2005; treatment continued until the 6-year visit or the last 
annual visit before December 1, 2008.  The overall study cohort for BARI 2D consisted of 2368 
participants.  The primary endpoint for BARI 2D was death from any cause, and the principal 
secondary endpoint was a composite of death, myocardial infarction, or stroke.  This manuscript 
reports the results of post hoc analyses that examine associations between baseline and time-
varying cardiovascular risk factors and PAD outcomes. 
 
Definition of Lower Extremity Outcomes 
The primary outcome reported in this manuscript is a composite lower extremity outcome used 
in previous BARI 2D analyses.  Participants were considered an “event” if they experienced any 
of the following lower extremity outcomes: decrease in ankle-brachial index to abnormal level 
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 (ABI ≤ 0.9), lower extremity revascularization, or lower extremity amputation.  1479 participants 
with normal ABI (0.91-1.30) at study entry were eligible for the primary analysis in this 
manuscript; those with abnormal ABI at baseline were excluded for reasons enumerated 
previously.  The range for normal ABI is chosen based on guidelines published in a 2003 ADA 
consensus statement regarding PAD in diabetes. 
 
Assays of Biomarkers 
The biomarker assays used in BARI 2D were previously reported by Sobel et al (34).  
Plasminogen activator inhibitor-1 (PAI-1) activity, PAI-1 antigen, tissue plasminogen activator 
(tPA), and insulin were measured in the fibrinolysis core laboratory at the University of Vermont 
in samples obtained at baseline, 1 month, 3 month, 6 month, and every 6 months thereafter over 
5 years of follow-up.  PAI-1 activity was assessed using a modified chromogenic substrate 
enzymatic assay developed by Chmielewska and Wiman.  PAI-1 antigen and tPA levels were 
determined with commercially available enzyme-linked immunoassay kits (Trinity Biochcech 
PLC, Bray, Wicklow, Ireland).  CRP, D-dimer, and fibrinogen were assayed at the same core 
laboratory as part of an ancillary study, with data through the first 24 months of follow-up.  
Fibronogen was measured by the Claus method, and D-dimer was measured 
immunoturbidimetrically with STA-Liatest D-Dimer reagents (Diagnostica Stago, Parsippany, 
New Jersey) on a STA Compact (Roche Professional Diagnostics, Basel, Switzerland).  HbA1c 
was assayed in whole blood samples in the BARI 2D chemistry laboratory in Minneapolis or 
core laboratories in Brazil and Europe. 
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 Statistical Methods 
Baseline descriptive statistics are reported as means ± SDs for continuous variables; medians and 
interquartile ranges are presented for skewed data, and proportions are reported for categorical 
variables.  The baseline distributions of all risk factors and biomarkers were compared across the 
assigned glycemic treatment arms using t-tests, Wilcoxon tests, and chi-squared tests for 
continuous, skewed continuous and categorical data, respectively.  Baseline characteristics are 
presented separately for the assigned glycemic treatment arms in order to accompany the 
stratified analyses described later in this section. 
 
Cox proportional-hazards models were used to estimate hazard ratios and associated 95% 
confidence intervals for the associations between each potential risk factor and composite lower 
extremity outcome.  Time-to-event was calculated from the date of randomization to first 
recorded lower extremity event; participants with no event were censored at their last full-
protocol follow-up visit.  Most predictor variables were examined as continuous variables; a log-
transformation was applied to those with skewed distributions and/or nonlinear associations with 
outcome.  The first series of Cox models were constructed to assess the effects of each risk factor 
while adjusting for known PAD risk factors that demonstrated significant univariate associations 
with PAD (age, sex, race, and baseline smoking status). 
 
To determine which of the baseline risk factors showed the strongest independent association 
with lower extremity outcomes when adjusting for other candidate variables as well as the 
aforementioned four “known” risk factors (age, sex, race, and smoking), we constructed a 
multivariate model using forward selection with age, sex, race, and baseline smoking status 
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 forced to enter the model plus all candidate variables that met a significance level of p≤0.10 also 
included in the final multivariate model.   
 
We then performed a similar process using the same risk factors assessed as time-varying 
covariates, updating each value annually to be consistent with the availability of updated ABI 
measurements (also performed annually).  Since previous BARI 2D analyses have shown 
differential trends in several candidate variables as well as differences in the incidence of lower 
extremity outcomes between glycemic control arms during the trial, we tested for interactions 
between assigned glycemic control strategy and each of the time-varying risk factors; there were 
several significant interactions between candidate variables and assigned treatment, suggesting 
that stratified analyses are appropriate.  Within each glycemic control arm, we constructed 
separate models for each potential risk factor (adjusting for age, sex, race, and smoking) and then 
created multivariate models determined by forward selection, using the same process described 
above for the baseline models. 
 
SAS version 9.2 (SAS Institute, Cary, NC) was used for all statistical analyses.  Nominal p-
values are reported; p-values less than 0.10 were considered statistically significant in this 
exploratory analysis, and no adjustment was made for multiple comparisons.   
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 4.4 RESULTS 
The BARI 2D trial enrolled 2368 participants with T2DM and coronary artery disease; baseline 
characteristics of the study population have been reported previously.129  Of the 2368 BARI 2D 
participants, 1479 were eligible for this paper’s primary analyses; the participants excluded were 
generally older, heavier, more likely to be current smokers, had higher systolic blood pressure, 
higher pulse pressure, and longer duration of diabetes than those included in this analysis.  Since 
most of those excluded were removed from the analysis due to pre-existing PAD, it is not 
surprising that excluded participants generally had more cardiovascular risk factors. 
 
Table 4-1 describes the baseline characteristics of the 1479 participants included in this paper’s 
primary analysis.  Participants included in our analytic sample were 61.9 ± 8.0 years, 72% male, 
15% identified as Black race, and 12% were current smokers.  Baseline distributions of BMI, 
lipids, blood pressure, HbA1c, albumin-creatinine ratio, and biomarkers of interest were similar 
between the assigned glycemic treatment groups; there were no significant differences in major 
demographic or clinical characteristics. 
 
Three hundred and three participants (20.5%) experienced one or more of the lower extremity 
outcomes included in the composite lower extremity outcome.  290 of these participants had at 
least one recorded low ABI during follow up, 25 had a lower extremity revascularization, and 13 
required a lower extremity amputation.  Table 4-2 displays the associations between baseline 
risk factors and incidence of the composite lower extremity outcome when adjusting for age, sex, 
race, and baseline smoking status (each of which was significantly associated with the composite 
outcome in a multivariate model; see Table 4-3).  Baseline HbA1c was significantly associated 
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 with the incidence of lower extremity outcomes (HR= 1.19, p<0.01).  Systolic blood pressure, 
pulse pressure, albumin-creatinine ratio, and C-reactive protein were also significantly associated 
with lower extremity outcomes when adjusting for age, sex, race, and smoking. 
 
Table 4-4 displays the results of a forward selection algorithm with age, sex, race, and smoking 
forced to enter the model and all other baseline variables shown in Table 2 eligible as candidates.  
HbA1c again shows the strongest association (HR=1.19, p<0.01), followed by log-transformed 
albumin-creatinine ratio (HR=1.08, p<0.05) and then log-transformed D-dimer (HR=1.15, 
p<0.10); the selection algorithm terminates after this step since no other variable is associated 
with outcome at p<0.10 significance level with the aforementioned variables included in the 
model.  Notably, D-dimer did not show a significant relationship in the first set of models, but 
was only significantly associated with outcome in models that also adjusted for HbA1c.  If D-
dimer is not considered a candidate variable, then CRP would enter the model instead, and if 
neither D-dimer nor CRP were candidate variables, then fibrinogen would enter the model; this 
is possibly due to correlation between these variables (Table 4-5). 
 
The observed associations are noticeably different when the risk factors are modeled as time-
varying covariates (Table 4-6); recall that these analyses are stratified due to the differential 
effects of assigned treatment on risk factors of interest.  Among those assigned to IP strategy, 
HbA1c is the strongest predictor (p<0.01) with albumin-creatinine ratio the only other candidate 
variable showing any significant relationship with the composite lower extremity outcome.  
Among those assigned to IS strategy, several predictors show significant relationships including 
BMI, lipids, systolic blood pressure, pulse pressure, albumin-creatinine ratio, and D-dimer.  
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 Notably, time-varying HbA1c is not a significant predictor for those assigned to IS therapy, 
although it was the strongest for those assigned to IP therapy. 
 
When using the forward selection algorithm, the stratified analyses show that the strength of 
selected risk factors’ association with outcome varies by glycemic control strategy (Table 4-7).  
Age, sex, smoking, and baseline HbA1c are strongly associated with outcome for the IP patients, 
while only moderately so for the IS patients.  Of the other candidate variables, baseline HbA1c 
and change in HbA1c are predictive of outcome in the IP patients, while baseline D-dimer and 
change in D-dimer are significantly associated with outcome in the IS patients (only after 
adjustment for HbA1c). 
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 4.5 DISCUSSION 
The BARI 2D trial was a randomized controlled trial designed to determine the optimal 
treatment strategy for patients with stable CAD suitable for elective revascularization and 
T2DM. All of these participants have clinically significant atherosclerosis in the coronary 
arteries; studying the incidence of new PAD and lower extremity outcomes is still informative 
because it represents the advancement of atherosclerosis into another vascular bed.  Using the 
BARI 2D data to identify risk factors for incident PAD in this population may lead to better 
mechanistic understanding of how insulin sensitizing and insulin providing medications affect 
the progression of atherosclerosis. 
 
Approximately 20% of BARI 2D participants with normal ABI at study entry experienced at 
least one lower extremity event (ABI ≤ 0.9, lower extremity revascularization, or lower 
extremity amputation) within five years of follow-up.  As expected, age, sex, race, and baseline 
smoking were significantly associated with incidence of lower extremity outcomes.  When 
adjusting for the aforementioned risk factors, baseline risk factors predictive of lower extremity 
events were high systolic blood pressure, pulse pressure, poor glycemic control (higher HbA1c), 
renal dysfunction (high albumin-creatinine ratio), and a marker of inflammation (CRP).  With 
the exception of pulse pressure, these are all well-established cardiovascular risk factors that 
have demonstrated a relationship with PAD incidence in prior research, and the relationship 
between pulse pressure and PAD risk is understandable given that pulse pressure is strongly 
associated with high systolic blood pressure. 
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 It is fascinating to note the variation between glycemic control strategies wherein different risk 
factors are predictive of PAD in our time-varying analyses.  We know from previous research 
that participants assigned to IS therapy experienced improvements in biomarker profiles not 
observed in those assigned the IP strategy; in addition to lower HbA1c, participants assigned to 
IS therapy had significantly greater in CRP, fibrinogen, tPA, PAI-1 activity, and PAI-1 antigen 
than participants assigned to IP therapy.98 However, in the stratified analysis with the biomarkers 
viewed as time-varying covariates and adjustment for changes in HbA1c, it was change in D-
dimer that was the most predictive of PAD risk in participants assigned to IS therapy, ironically 
the only one of the biomarkers that did not differ over time between the glycemic control arms.  
If D-dimer were not considered a candidate variable for this model, then CRP would have 
entered the model as a predictor of PAD incidence, and the same is true for fibrinogen.  These 
relationships were significant only in participants assigned to IS therapy.  It is possible that the 
improved biomarker profiles in the patients assigned IS therapy signified an environment less 
favorable to further development of atherosclerosis than that present in patients assigned to IP 
therapy.  In contrast, HbA1c showed a much stronger association with the incidence of PAD in 
participants assigned to IP therapy.   
 
It is difficult to say why the magnitude of time-varying change in HbA1c’s relationship with 
PAD was different in the glycemic treatment arms.  Adjusting for age, sex, race, and smoking 
status, our results showed a statistically significant 17% increased hazard ratio in those assigned 
to IP therapy for each 1% increase in HbA1c, but a nonsignificant 5% increased hazard in those 
assigned to IS therapy.  One possibility is that the better overall glycemic control in the IS arm 
dampened the effects of HbA1c on PAD outcomes by pushing the majority of participants into 
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 an HbA1c range where there was relatively little effect of glycemic control on the development 
of new atherosclerosis, while a greater proportion of participants in the IP arm remained in a 
higher range of HbA1c and therefore may have been in a range where there was more of an 
effect on atherosclerosis. 
 
As mentioned briefly above, our baseline models showed relationships generally consistent with 
prior research regarding traditional cardiovascular risk factors and PAD.  Both systolic blood 
pressure (SBP) and pulse pressure were associated with lower extremity outcomes in our 
baseline models.  Hypertension is not a direct cause of atherosclerosis per se, but it may promote 
atherosclerosis by its effects on the vasculature.  Arteries exposed to hypertension have increased 
permeability, which results in an increased ability of oxidized lipoproteins to migrate into the 
intima,35 and hypertension also may affect vascular wall remodeling by altering the balance 
between cellular proliferation and apoptosis.36 SBP is one of the components used to calculate 
the ankle-brachial index and is also an established predictor of PAD from previous research,  so 
one would expect a significant association between SBP and PAD incidence.  Increased pulse 
pressure is generally indicative of arterial stiffness, thought to be more damaging to the heart 
than to the peripheral vasculature, so it is interesting to note that pulse pressure also demonstrates 
a strong relationship with PAD; however, since pulse pressure is strongly related to SBP, it is not 
surprising to see a strong association between pulse pressure and risk of PAD. 
 
HbA1c has demonstrated a positive association with increased risk of PAD in several studies.  
The United Kingdom Prospective Diabetes Study (UKPDS) showed that each 1% increase in 
HbA1c was associated with a 28% increased risk of PAD,90 later confirmed by a meta-analysis 
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 showing the same estimated 28% increased PAD risk per 1% increase in HbA1c.91 Several 
plausible biological mechanisms have been proposed to explain a possible relationship between 
chronically elevated blood glucose levels and atherosclerosis.148 Glucose can react with many 
different proteins, causing structural alterations and subsequently impaired protein and tissue 
function; such alterations may contribute to endothelial dysfunction, changes in arterial 
distensibility, plaque formation, and atherosclerosis.149,150,151,152 
 
Higher albumin-creatinine ratio, indicative of worsening kidney function, was also predictive of 
lower extremity outcomes in BARI 2D.  Because the kidney is a highly vascular organ, it could 
be argued that systemic atherosclerotic disease could be associated with declining renal function, 
but the directionality of this relationship is largely unclear.  Cross-sectional data from NHANES 
1999-200040 and the Cardiovascular Health Study153 both demonstrated a relationship between 
chronic kidney disease and abnormal ABI; however, as cross-sectional studies, these studies 
show nothing about temporality.  Longitudinal results from the ARIC study suggested that 
reduced eGFR was a risk factor for incident PAD,154 and the BARI 2D data presented here also 
suggest that higher albumin-creatinine ratio was predictive of incident peripheral arterial disease, 
suggesting that renal insufficiency may be causally related to progression of atherosclerosis.  
Potential physiological mechanisms by which renal dysfunction might affect the atherosclerotic 
process include altered calcium-phosphorus metabolism, homocysteine metabolism, 
lipoprotein(a) metabolism and alterations in inflammatory and coagulation pathways.155,156   
 
C-reactive protein, fibrinogen, and D-dimer also showed significant associations with PAD risk 
in one or more of the models presented in this paper.  Since these biomarkers are representative 
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 of distinct but interrelated processes pertaining to inflammation, coagulation, and thrombosis and 
their values are somewhat correlated, particularly fibrinogen and CRP, often they would not 
show predictive value when placed in models together, but when any one of the three was 
considered a candidate variable, they showed a significant association with PAD risk (although, 
for fibrinogen, this was only true when viewed as a time-varying covariate; baseline fibrinogen 
showed no predictive value for PAD incidence).  Both CRP and fibrinogen have been associated 
with PAD in cross-sectional studies,143 and fibrinogen has been associated with increased risk of 
developing PAD in diabetes.97  NHANES data has also showed that participants in the highest 
quartile of CRP and fibrinogen had a 2.0-fold increased odds of prevalent PAD compared with 
participants in the lowest quartiles.69  Among individuals with existing PAD, higher levels of 
inflammatory biomarkers are associated with increased mortality, increased cardiovascular 
mortality, and increased risk of failure of lower-extremity revascularization procedures.77,78,79  To 
our knowledge, no previous research has shown changes in D-dimer to be linked to increased 
risk of PAD incidence; two studies have shown D-dimer associated with risk of functional 
decline in patients with existing PAD.75,76 
 
Our study findings must be considered carefully in context of the trial’s strengths and limitations.  
This is a post-hoc secondary analysis of a randomized controlled trial in which all participants 
had CAD and T2DM; the effects of these risk factors may be different in the general population.  
Several of the biomarkers included in this analysis, including CRP and fibrinogen, were only 
collected through 24 months of follow-up, and thus their relationships with PAD risk in our 
analyses using time-varying covariates may not be fully accurate.  It also should be noted that 
our primary outcome was a composite of low ABI, lower extremity revascularization, and lower 
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 extremity amputation used in a prior BARI 2D publication on peripheral arterial disease.  We felt 
this outcome was appropriate because ABI was only measured annually, and wished to capture 
lower extremity events of clinical significance that may have occurred without a low ABI being 
measured. 
 
We have previously reported the baseline prevalence of PAD in the BARI 2D trial and the 
baseline risk factors associated with prevalent PAD at study entry131 as well as the incidence of 
PAD in each glycemic control arm. 147  This manuscript extends our previous work by reporting 
the associations between traditional and nontraditional risk factors for PAD and lower extremity 
outcomes during follow-up.  After adjusting for age, sex, race, and smoking, our data showed 
that hypertension, HbA1c, albumin-creatinine ratio, and several biomarkers indicative of 
inflammation and antithrombotic activity were positively associated with PAD risk.  It is 
uncertain whether these are causal relationships between the risk factors and PAD, or whether 
these are merely reflective of advancing systemic disease.  Nonetheless, it appears that in 
addition to high HbA1c, several nontraditional risk factors such as CRP, fibrinogen, and D-dimer 
may have potential to identify T2DM patients at highest risk for developing further 
atherosclerosis. 
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 4.6 CONCLUSION 
This manuscript reports the associations between traditional and nontraditional risk factors for 
PAD and lower extremity outcomes during follow-up.  After adjusting for known PAD risk 
factors of age, sex, race, and smoking, our data showed that hypertension, HbA1c, renal 
dysfunction, and biomarkers indicative of inflammation, coagulation, and fibrinolysis were 
positively associated with PAD risk.  It is uncertain whether these are causal relationships or 
merely reflective of advancing systemic disease.  Nonetheless, it appears that in addition to high 
HbA1c, several nontraditional risk factors such as CRP, fibrinogen, and D-dimer may have 
potential to identify T2DM patients at highest risk for developing further atherosclerosis.  
Notably, the markers of inflammation, coagulation, and fibrinolysis were associated with lower 
extremity outcomes among patients treated with insulin sensitizing medications, but this was not 
the case for patients treated with insulin providing medications, suggesting that these 
medications may have a differential effect on these processes and subsequently on the 
development of atherosclerosis in patients with type 2 diabetes. 
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 4.7 TABLES AND FIGURES 
Table 4-1. Baseline Characteristics of Participants Available for PAD Analysis 
Characteristic 
IP 
(N=744) 
IS 
(N=735) p-value 
Age (years) 62.0 ± 8.7 61.8 ± 8.9 0.633 
Gender (male), % 71.9 71.4 0.858 
Black Race, % 14.7 16.2 0.402 
Current Smoker, % 11.5 11.6 0.925 
BMI (kg/m2) 31.4 ± 5.6 31.6 ± 5.9 0.453 
LDL cholesterol (mg/dl) 96.8 ± 31.8 94.5 ± 33.1 0.177 
HDL cholesterol (mg/dl) 38.3 ± 10.2 37.6 ± 9.5 0.213 
Triglycerides (mg/dl) 183.3 ± 149.5 177.7 ± 123.6 0.437 
Systolic Blood Pressure (mm Hg) 130.2 ± 19.2 130.9 ± 18.7 0.474 
Diastolic Blood Pressure (mm Hg) 74.4 ± 10.7 75.0 ± 11.0 0.302 
Pulse Pressure (mm Hg) 55.9 ± 15.1 55.7 ± 14.7 0.780 
HbA1c (%) 7.7 ± 1.6 7.6 ± 1.6 0.107 
ACR (mg/g)^ 10.9 (5.2-34.6) 10.8 (4.8-42.4) 0.826 
CRP (ug/mL)^ 2.1 (1.0-5.7) 2.2 (1.0-5.2) 0.720 
Fibrinogen (mg/dl)^ 356 (295-422) 350 (291-409) 0.232 
D-Dimer (μg/ml FEU)^ 0.32 (0.19-0.57) 0.30 (0.18-0.55) 0.781 
PAI-1 activity (au/ml)^ 16.0 (10.0-27.0) 16.0 (10.0-26.0) 0.960 
PAI-1 antigen (ng/ml)^ 23.0 (15.0-35.0) 23.0 (15.0-34.0) 0.406 
TPA (ng/ml)^ 9.6 (7.3-12.0) 9.7 (7.2-12.0) 0.638 
^Presented as median (Q1-Q3) 
IP = Insulin Providing Assignment; IS = Insulin Sensitizing Assignment; BMI= Body Mass 
Index; LDL=Low-Density Lipoprotein; HDL=High-Density Lipoprotein; HbA1c=Hemoglobin 
A1c; ACR=Albumin/Creatinine Ratio; CRP= C-Reactive Protein; PAI-1 = Plasminogen 
Activator Inhibitor-1; TPA= Tissue Plasminogen Activator 
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Table 4-2. Associations^ Between Baseline Risk Factors and Incidence of Lower Extremity 
Outcomes 
Risk Factor Hazard Ratio 95% CI 
BMI 1.01 0.99-1.03 
LDL cholesterol (per 10 mg/dl) 1.01 0.97-1.05 
HDL cholesterol (per 10 mg/dl) 0.99 0.81-1.05 
Triglycerides (per 10 mg/dl) 1.00 0.99-1.01 
Systolic Blood Pressure  (per 10 mm Hg) 1.05* 0.99-1.11 
Diastolic Blood Pressure (per 10 mm Hg) 0.97 0.86-1.08 
Pulse Pressure (per 10 mm Hg) 1.11** 1.03-1.19 
HbA1c (per 1.0%) 1.18*** 1.10-1.26 
Log(ACR) 1.13** 1.06-1.21 
Log(CRP) 1.10* 1.00-1.21 
Log(D-Dimer) 1.09 0.96-1.24 
Log(Fibrinogen) 1.06 0.68-1.66 
Log(PAI-1 Activity) 0.97 0.82-1.16 
Log(PAI-1 Antigen) 1.01 0.84-1.22 
Log(TPA) 0.80 0.61-1.06 
^ separate models for each candidate variable; each model adjusted for age, sex, race, and 
smoking status 
BMI= Body Mass Index; LDL=Low-Density Lipoprotein; HDL=High-Density Lipoprotein; 
HbA1c=Hemoglobin A1c; ACR=Albumin/Creatinine Ratio; CRP= C-Reactive Protein; 
PAI-1 = Plasminogen Activator Inhibitor-1; TPA= Tissue Plasminogen Activator 
*P<0.10; **P<0.05; ***P<0.01 
85 
  
 
Table 4-3. Multivariate Associations^ Between Selected Variables and Incidence of Lower 
Extremity Outcomes 
Risk Factor Hazard Ratio 95% CI 
Age (Per 10 years) 1.32 1.19-1.46 
Sex (Female vs. Male) 1.55 1.22-1.98 
Race (Black vs. non-Black) 1.47 1.11-1.94 
Smoking (Current vs. Former/Never) 2.07 1.52-2.83 
^Variables simultaneously included in multivariate Cox proportional-hazards model 
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 Table 4-4. Multivariate Associations^ Between Baseline Risk Factors and Incidence of 
Lower Extremity Outcomes 
Forced Into Model Hazard Ratio 95% CI 
Age (per 10 years) 1.34*** 1.17-1.52 
Sex (Female vs. Male) 1.45*** 1.10-1.92 
Race (Black vs. non-Black) 1.40** 1.01-1.93 
Smoking (Current vs. Former/Never) 2.38*** 1.67-3.41 
Additional Candidate Variables Hazard Ratio 95% CI 
HbA1c (per 1.0%) 1.19*** 1.10-1.29 
Log(ACR) 1.08** 1.00-1.17 
Log(D-Dimer) 1.15* 0.99-1.34 
^Model created using forward selection algorithm with age, sex, race, and smoking forced to 
enter model and all risk factors listed in Table 2 eligible as candidate variables 
HbA1c=Hemoglobin A1c; ACR=Albumin/Creatinine Ratio 
*P<0.10; **P<0.05; ***P<0.01 
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 Table 4-5. Correlations Between Baseline Values of Candidate Variables 
 BMI LDL HDL Trig SBP DBP PP A1c ACR CRP D-Dm Fibr PAI-1 Act 
PAI-1 
Ant TPA 
BMI  -0.007 -0.439 0.045 0.034 0.016 0.027 -0.013 0.032 0.150 0.019 0.136 0.205 0.168 0.039 
LDL   0.144 0.004 0.125 0.172 0.036 0.155 0.069 0.058 -0.027 0.045 -0.016 -0.011 0.074 
HDL    -0.329 0.105 0.031 0.111 0.008 0.086 -0.051 -0.018 0.007 -0.180 -0.169 -0.169 
Triglycerides     -0.046 0.022 -0.075 0.152 0.084 -0.003 -0.030 0.079 0.304 0.272 0.284 
SBP      0.619 0.820 0.031 0.179 -0.011 0.007 0.041 -0.022 -0.015 -0.047 
DBP       0.060 0.102 0.090 -0.023 -0.075 -0.002 0.089 0.089 0.076 
PP        -0.036 0.164 0.004 0.063 0.054 -0.094 -0.086 -0.116 
HbA1c         0.129 0.046 -0.004 0.129 0.027 0.041 0.063 
ACR          0.057 0.088 0.203 -0.046 -0.048 -0.027 
CRP           0.163 0.442 0.027 0.036 0.077 
D-Dimer            0.114 -0.069 -0.019 -0.001 
Fibrinogen             0.009 0.016 0.194 
PAI-1 Activity              0.812 0.369 
PAI-1 Antigen               0.422 
TPA                
BMI= Body Mass Index; LDL= Low-Density Lipoprotein Cholesterol; HDL= High-Density Lipoprotein Cholesterol; Trig= Triglycerides; SBP= Systolic Blood 
Pressure; DBP= Diastolic Blood Pressure; PP= Pulse Pressure; A1c=Hemoglobin A1c; ACR= Albumin/Creatinine Ratio; CRP= C-Reactive Protein; D-Dm = D-
Dimer; Fibr= Fibrinogen; PAI-1 Act = PAI-1 Activity; PAI-1 Ant= PAI-1 Antigen; TPA= Tissue Plasminogen Activator 
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 Table 4-6. Associations^ Between Time-Varying Risk Factors and Incidence of Lower 
Extremity Outcomes, Stratified By Assigned Glycemic Treatment 
 IP Patients 
(N=744) 
IS Patients 
(N=735) 
Risk Factor Hazard Ratio 95% CI Hazard Ratio 95% CI 
Body Mass Index 1.00 0.98-1.03 1.04*** 1.01-1.06 
LDL (per 10 mg/dl) 1.03 0.97-1.08 1.06** 1.00-1.11 
HDL (per 10 mg/dl) 0.99 0.85-1.13 0.79** 0.62-0.96 
Triglycerides (per 10 mg/dl) 1.00 0.99-1.01 1.01 1.00-1.02 
Systolic BP  (per 10 mm Hg) 1.00 0.91-1.10 1.13** 1.03-1.23 
Diastolic BP (per 10 mm Hg) 0.96 0.80-1.12 0.96 0.78-1.14 
Pulse Pressure (per 10 mm Hg) 1.02 0.91-1.13 1.19** 1.07-1.32 
HbA1c (per 1.0%) 1.17*** 1.06-1.29 1.05 0.93-1.19 
Log(ACR) 1.08* 0.97-1.18 1.11* 1.00-1.23 
Log(CRP) 1.10 0.97-1.25 1.09 0.94-1.26 
Log(D-Dimer) 1.02 0.84-1.22 1.29* 1.05-1.58 
Log(Fibrinogen) 1.45 0.84-2.52 1.29 0.65-2.57 
Log(PAI-1 Activity) 1.00 0.84-1.21 1.07 0.85-1.35 
Log(PAI-1 Antigen) 0.99 0.78-1.26 1.14 0.85-1.51 
Log(TPA) 0.98 0.65-1.48 0.95 0.65-1.40 
^ separate models for each candidate variable; each model adjusted for age, sex, race, and 
smoking status 
IP = Insulin Providing Assignment; IS = Insulin Sensitizing Assignment; BMI= Body Mass 
Index; LDL=Low-Density Lipoprotein; HDL=High-Density Lipoprotein; HbA1c=Hemoglobin 
A1c; ACR=Albumin/Creatinine Ratio; CRP= C-Reactive Protein; PAI-1 = Plasminogen 
Activator Inhibitor-1; TPA= Tissue Plasminogen Activator 
*P<0.10; **P<0.05; ***P<0.01 
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Table 4-7. Multivariate Associations^ Between Time-Varying Risk Factors and Incidence 
of Lower Extremity Outcomes, Stratified By Assigned Glycemic Treatment 
 IP Patients 
(N=744) 
IS Patients 
(N=735) 
 Hazard 
Ratio 95% CI 
Hazard 
Ratio 95% CI 
Age (per 10) 1.45*** 1.23-1.67 1.22* 0.97-1.48 
Sex (Female) 1.53** 1.08-2.17 1.45* 0.94-2.24 
Race (Black) 1.46 0.97-2.18 1.37 0.83-2.26 
Smoking (Current) 2.95*** 1.91-4.56 1.80* 0.99-3.26 
Baseline HbA1c 1.24** 1.10-1.40 1.14 0.97-1.35 
Change in HbA1c 1.13** 1.01-1.26 0.89 0.76-1.04 
Baseline Log(D-Dimer) Not Included 1.38** 1.04-1.81 
Change in Log(D-Dimer) Not Included 1.30** 1.00-1.68 
^Stratified models created using forward selection algorithm with age, sex, race, and smoking 
forced to enter model and all risk factors listed in Table 2 eligible as candidate variables 
*P<0.10; **P<0.05; ***P<0.01 
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 5.0  MANUSCRIPT 3: MEASUREMENT VARIATION OF THE ANKLE-BRACHIAL 
INDEX WITH AUTOMATED OSCILLOMETRIC DEVICE VERSUS DOPPLER 
ULTRASOUND 
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 5.1 ABSTRACT 
Objective: This data collection project was designed to evaluate the reproducibility and 
reliability of ankle-brachial index (ABI) measurements obtained using 1) the Colin VP-1000 
oscillometric device and 2) the Doppler ultrasound method. 
Research Design and Methods: This project was carried out at the University of Pittsburgh’s 
Epidemiology Ultrasound Research Laboratory.  40 participants were enrolled, each of whom 
had their ABI measured in the same sequence (Colin, Doppler, Colin, Doppler) so that each 
participant had two ABI measurements taken with Colin and two ABI measurements taken with 
Doppler, allowing for within-method reproducibility as well as between-method comparisons.   
Results: Within-subject agreement was reasonable for the Colin (intra-class correlation = 0.77), 
and 36 of 40 participants (90.0%) had an absolute difference ≤ 0.10 between the two Colin 
measurements.  Within-subject agreement was even stronger for the two Doppler measurements 
(intra-class correlation = 0.91); 38 of 40 participants (95.0%) had an absolute difference ≤ 0.10 
between the two Doppler measurements.  The between-method agreement was less than ideal 
(intra-class correlation coefficient = 0.44); Doppler ABI measurements tended to be higher than 
Colin ABI measurements on the same participant, and only 26 of 40 participants (65.0%) had an 
absolute difference ≤ 0.10 between the two methods. 
Conclusions: The Colin VP-1000 is capable of measuring ABI with an acceptable level of 
reproducibility; however, agreement between the Colin and the gold-standard Doppler method is 
less than ideal.  Our study results do not support the replacement of Doppler ABI measurements 
with Colin ABI measurements in a clinical setting. 
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 5.2 INTRODUCTION 
The ankle-brachial index (ABI) is the principal screening technique for peripheral arterial disease 
(PAD)157 and an established predictor of cardiovascular morbidity and mortality.23,24,25,26  Also 
known as the ankle-arm index (AAI) or ankle-brachial pressure index (ABPI), the ABI is a 
simple ratio of the systolic blood pressure measured at the ankle divided by the brachial systolic 
blood pressure.  ABI measurements ranging from 0.91-1.30 are considered normal; an ABI≤0.9 
is suggestive of atherosclerotic PAD, while an ABI>1.3 suggests the presence of medial arterial 
calcification, making it difficult to obtain an accurate reading in the lower extremity (1).  
Epidemiologic studies have shown that patients with abnormal ABI at either end of the spectrum 
have an increased risk of cardiovascular events and mortality.24,25 
 
The most common method of measuring ABI uses a continuous-wave Doppler probe for 
detection of arterial flow and a pneumatic cuff to determine systolic blood pressure in each limb.  
The pneumatic cuff is placed over the appropriate limb and inflated until arterial flow ceases 
noted by the lack of audible sound heard on the Doppler; the cuff is then deflated slowly until the 
flow signal reappears, and the cuff pressure at reappearance of a signal is the systolic pressure 
for that limb.  The systolic pressure at each ankle is divided by the higher of the two brachial 
pressures to calculate the ABI for each leg.  In 1969, Yao et al published the first study to report 
measurement of ankle blood pressures using the Doppler method.109,110 Despite some 
controversy regarding appropriate measurement protocol158 and calculation159,160 of the ankle-
brachial index using Doppler, a 2012 AHA Scientific Statement concludes that the Doppler 
method is to be the most reliable way to determine ABI and provides guidelines for 
standardization.157  
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 The principal alternative to the Doppler method relies on oscillometric measurement of blood 
pressure at each limb.  The Colin VP-1000 oscillometric device allows simultaneous pressure 
measurement at each of the brachial arteries as well as the posterior tibial arteries in each ankle.  
Oscillometers measure the magnitude of pressure vacillation at each arterial site as the cuffs are 
simultaneously deflated from suprasystolic pressures; as pressure in the cuff decreases and 
approaches systolic blood pressure, oscillation rapidly increases and eventually reaches a peak, 
after which decrease of the cuff pressure causes oscillation to decrease.  Systolic blood pressure 
is calculated when the oscillation increases rapidly; diastolic blood pressure is calculated when 
the oscillation decreases rapidly.  The ABI is calculated by dividing the systolic pressure at each 
ankle by the higher of the two brachial systolic pressures to establish ABI for each leg. 
 
Automated devices such as the Colin have several advantages over the Doppler method for 
measuring ABI.  The Doppler method requires a trained sonographer or physician and can still 
be prone to measurement biases and errors; in contrast, measuring ABI with the Colin requires 
little specialized training and is free of bias.  The Doppler method is also time-consuming, while 
the Colin reduces the time required to obtain an ABI by measuring all four limbs simultaneously.  
The time required for measurement is one of the barriers to the inclusion of ABI in regular office 
visits; the ability to measure ABI in less time and without highly trained personnel could make it 
more practical to include as part of routine office visits.  However, before the Colin can be 
recommended for mainstream use, it must be proven accurate and reliable when compared 
against the gold-standard Doppler method. 
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 Most studies to date have shown reasonable agreement between oscillometric ABI measurements 
and Doppler ABI measurements; the aforementioned 2012 AHA Scientific Statement (1) on the 
ankle-brachial index concluded that correlation between the two methods is acceptable, although 
the studies upon which this statement was based used varying criteria to define an acceptable 
level of agreement.  It should be noted that some discrepancies may be partially explained by 
differences in measurement protocol; for example, most oscillometric devices (including the 
Colin described in this manuscript) measure the ankle pressure at the posterior tibial (PT) artery, 
while Doppler measurements are sometimes taken at the dorsalis pedis (DP) artery since it can 
be easier to locate the DP pulse in the ankle than the PT pulse. 
 
In addition to evaluating agreement between Colin measurements and Doppler measurements, 
we must also establish within-method reproducibility for each technique.  To date, Doppler 
measurements have generally shown slightly better reproducibility than oscillometric ABI 
measurements161,162 although oscillometric devices have demonstrated acceptable reproducibility 
for use in research studies.163,164  In the present study, we report within-method reproducibility 
for ABI measurements taken with the Colin VP-1000 oscillometric device at the Epidemiology 
Ultrasound Research Laboratory (URL) at the University of Pittsburgh, as well as within-method 
reproducibility for ABI measurements using the traditional Doppler method.  We also report 
between-method agreement for Colin ABI measurements against Doppler ABI measurements. 
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 5.3 METHODS 
The URL at the University of Pittsburgh conducts noninvasive vascular testing for 
epidemiological research studies, and therefore must evaluate validity and reproducibility of its 
research measurements for quality control.  The present study has three aims: i) evaluate the 
reproducibility of ABI measured with the Colin VP-1000 oscillometric device, ii) evaluate the 
reproducibility of ABI measured with the Doppler method, and iii) evaluate agreement between 
the two methods.  
 
Participant Recruitment and Enrollment 
The study was approved by the Institutional Review Board of the University of Pittsburgh.  
Volunteers were recruited through advertisements posted in the URL and the Graduate School of 
Public Health at the University of Pittsburgh, as well as verbal invitations issued by the Principal 
Investigator and/or laboratory staff members.  Fifty-four potential participants agreed to schedule 
a study visit; forty (74.1%) attended the scheduled visit and completed all study procedures. 
 
Study Visit Procedure 
Participants were greeted at the URL by the principal investigator and gave informed consent.  
Next, they completed a pretest questionnaire with information about basic demographics, known 
comorbidities of peripheral arterial disease (diabetes, high blood pressure, and high cholesterol) 
and three behaviors that might acutely affect ABI: smoking, caffeine consumption, and exercise. 
Specifically, participants were asked whether they had smoked, consumed caffeine, or exercised 
since midnight; since most visits occurred in the morning or early afternoon, this determines 
whether they had performed the behavior within approximately 12 hours of their visit.  
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 Participants were also asked to report the time and provide appropriate details (for example, a 
participant that reported consumption of caffeine was asked to report the beverage consumed - 
i.e. tea, coffee, soft drink, energy drink - as well as the number of cups consumed).  Participants 
were not asked to refrain from these behaviors, but the data were available to perform sensitivity 
analyses.  After completing the questionnaire, participants were escorted into an exam room, 
asked to remove their socks and shoes, and instructed to rest in the supine position for 5 minutes.  
After the rest period, the attending observer entered the room and began the examination.   
 
Clinical Examination 
The observer first obtained simultaneous blood pressure readings at the right and left brachial 
and posterior tibial arteries using the VP-1000 according to the protocol outlined in Appendix A.  
After the first VP-1000 measurement, the observer allowed 5 minutes for the vessels to return to 
resting state, then began the sequence of pressure measurements required to calculate ABI using 
the Doppler: first the right brachial pressure, then the left brachial pressure, then the right ankle 
pressure, and finally the left ankle pressure according to the protocol outlined in Appendix B.  
The observer again allowed a 5-minute rest period, and the process was repeated so each 
participant had two ABI measurements taken with each method (four ABI measurements total) 
in the following sequence: Colin #1, Doppler #1, Colin #2, and Doppler #2.  Once all four ABI 
measurements were finished, the observer handed the data collection forms to the principal 
investigator to verify that form was completed appropriately.  The principal investigator asked 
the participant if they had any questions or concerns, awarded the participant compensation and 
the visit was concluded. 
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 Baseline Characteristics of Study Participants 
We describe the study population using baseline characteristics from the pretest questionnaire, 
reporting means ± standard deviations for continuous variables and proportions for categorical 
variables.  Much of this data is self-reported on the pretest questionnaire, so accuracy cannot be 
guaranteed; however, these are not primary analytical variables in our study 
 
Statistical Methods: Notation 
Please refer to the following definitions while reviewing the statistical methods: 
 
 Colin1i= first Colin ABI measurement on the ith participant 
 Colin2i= second Colin ABI measurement on the ith participant 
 |Colin2i - Colin1i| = absolute value of the difference between the ith participant’s second Colin 
ABI and the ith participant’s first Colin ABI 
 ColinAVGi = average of the two Colin measurements on the ith participant 
 ColinAVG¯¯¯¯¯¯¯  = overall mean of all participants’ Colin ABI measurements 
 
 Doppler1i= first Doppler ABI measurement on the ith participant 
 Doppler2i= second Doppler ABI measurement on the ith participant 
 |Doppler2i - Doppler1i| = absolute value of the difference between the ith participant’s second 
Doppler ABI and the ith participant’s first Doppler ABI 
 DopplerAVGi = average of the two Doppler measurements on the ith participant 
 DopplerAVG¯¯¯¯¯¯¯¯  = overall mean of all participants’ Doppler ABI measurements 
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 Statistical Analysis: Within-Method Comparisons 
We report the linear correlation coefficient and intra-class correlation coefficient between paired 
measurements for each method (i.e. Colin1i vs. Colin2i), and we also report the mean difference 
between measurements for each method (i.e. Colin2i - Colin1i) with a 95% confidence interval for 
the difference.  We produced scatterplots and Bland-Altman plots for a graphical representation.  
The Bland-Altman plots show the difference between measurements (i.e. Colin2i - Colin1i) on the 
y-axis versus the average of the two measurements (ColinAVGi) on the x-axis, with reference lines 
drawn at the limits of agreement (mean difference ± 1.96*SD).  We also report the mean 
absolute difference (|Colin2i - Colin1i|) and the proportion of participants with absolute difference 
< 0.10 between measurements.  Each of the analyses described here were performed for both the 
Colin measurements and the Doppler measurements. 
 
Statistical Analysis: Between-Method Comparisons 
We performed similar statistical analyses to evaluate between-method agreement of the Colin 
ABI measurements against the Doppler method.  We calculated the linear correlation coefficient 
and intra-class correlation coefficient between the averaged measurements of each method 
(ColinAVGi vs. DopplerAVGi), and again produced a scatterplot and Bland-Altman plot for 
graphical representation.  For the between-method comparison, the Bland-Altman plot shows the 
difference between the averaged Colin measurements and averaged Doppler measurements 
(ColinAVGi - DopplerAVGi) on the y-axis versus the overall average of the paired measurements on 
the x-axis.  We also report the mean absolute difference (|ColinAVGi - DopplerAVGi|) between 
methods and the proportion of subjects with absolute difference < 0.10 between methods. 
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 Power and Sample Size 
We performed sample size calculations based on an equivalence test for paired means165 with 
significance level α = 0.05 and the following hypotheses:   
 
Ho: ColinAVG¯¯¯¯¯¯¯  - DopplerAVG¯¯¯¯¯¯¯¯  ≤ - 0.10 OR  ColinAVG¯¯¯¯¯¯¯  - DopplerAVG¯¯¯¯¯¯¯¯  ≥ 0.10    
Ha: -0.10 < ColinAVG¯¯¯¯¯¯¯  - DopplerAVG¯¯¯¯¯¯¯¯  < 0.10 
 
We chose 0.10 as the limit of equivalence since ABI is often categorized into intervals of that 
width in epidemiologic studies.  We assumed standard deviation of 0.15 for both Colin ABI and 
Doppler ABI measurements based on previously published studies and expert opinion.164,166   
This sample size calculation also requires estimating the between-method correlation; for the 
equivalence test specified here, there is a negative association between the between-method 
correlation and the required sample size to guarantee a fixed level of power, meaning that 
smaller between-method correlation requires a larger sample size to declare equivalence.  Thus, 
underestimating the between-method correlation is the conservative approach since it yields a 
larger sample-size estimate than overestimating the between-method correlation.  A systematic 
review comparing oscillometric methods and Doppler reported a pooled correlation of 0.71 
between methods;120 however, this review included many studies that used oscillometric devices 
other than the Colin, so we cannot be certain that the Colin will have the same level of 
correlation with Doppler.  Therefore, we performed sample size calculations using lower 
estimates of the correlation (0.2, 0.4, 0.6), noting that if the actual correlation was greater than 
our chosen estimates, we would retain sufficient power to declare equivalence between methods. 
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 Under the conditions outlined above, a sample size of 33 pairs with correlation 0.4 (Table 5-1) 
has 90% power to detect equivalence when the margin of equivalence is from -0.10 to 0.10 and 
the actual mean difference is 0.  We set an enrollment target of 40 participants to account for 
unusable data.  The additional sample size also allowed us to perform useful sensitivity analyses. 
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 5.4 RESULTS 
Characteristics of Study Participants 
Table 5-2 displays baseline characteristics of our study participants.  Participants were generally 
young (mean age 35.4 ± 11.9 years, range 22-63 years) and the majority self-reported white race 
(82.5%), although the sample also included black (7.5%) and Asian (10.0%) participants.  The 
sample included both males (30.0%) and females (70.0%).  Most participants were normal 
weight (65.0%) or overweight (22.5%), with five (12.5%) meeting criteria for “obese” according 
to BMI (calculated from self-report height and weight).  Few participants reported common PAD 
comorbidities such as diabetes (5.0%), high blood pressure (10.0%), or high cholesterol (12.5%).  
No participants reported smoking within a 12-hour window preceding the visit, 25 participants 
(62.5%) reported consuming caffeine prior to their study visit, and 16 participants (40.0%) 
reported exercising prior to their study visit. 
 
Distribution of Individual Pressure Measurements 
The mean and standard deviation of each pressure component involved in the calculation of ABI 
(left brachial, right brachial, left ankle, right ankle) are shown in Table 5-3 for each of the four 
ABI measurements performed in this study (Colin #1, Doppler #1, Colin #2, Doppler #2).  
Notably, while the brachial pressures were distributed similarly across all four measurements, the 
ankle pressures recorded with the gold-standard Doppler method were an average of 7.7 mm Hg 
higher than those recorded with the Colin.  This difference was present in the first and second 
measurement run.  Discussed in detail later in this manuscript, the difference in ankle pressures 
should manifest itself as slightly higher ABI measurements with the Doppler than with the Colin. 
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 Colin Reproducibility 
The first Colin measurement and second Colin measurement each have approximately normal 
distributions with no significant difference in the mean ABI from the first run to the second run 
(first: 1.05 ± 0.11, second: 1.08 ± 0.09, Table 5-4).  Within-subject agreement was reasonably 
good across the two Colin measurements, with an intra-class correlation coefficient = 0.77 and a 
linear correlation coefficient = 0.81 (Figure 5-1).  The within-subject differences between the 
first and second Colin measurements followed an approximately normal distribution with mean 
0.03 (95% CI: -0.03, 0.09).  The mean absolute difference was 0.06 (SD=0.04), and 36 of 40 
participants (90.0%) had an absolute difference ≤ 0.10 between the two Colin measurements.  
Only one of the 40 participants had a difference outside Bland-Altman limits of agreement 
(Figure 5-2) calculated based on the distribution of Colin measurements in our study. 
 
Doppler Reproducibility 
As reported for the Colin, the distributions of each of the Doppler ABI measurements were 
approximately normal with no significant difference in the mean ABI from the first to the second 
(first: 1.14 ± 0.13, second: 1.15 ± 0.12, Table 5-4).  Within-subject agreement was strong for the 
Doppler, with intra-class correlation = 0.91 and linear correlation = 0.92 (Figure 5-3).  The 
within-subject differences between the first and second Doppler measurements followed an 
approximately normal distribution with mean 0.01 (95% CI: -0.05, 0.07).  The mean absolute 
difference was 0.04 (SD=0.04), and 38 of 40 participants (95.0%) had absolute difference ≤ 0.10 
between the two Doppler measurements.  Two of 40 participants fell outside Bland-Altman 
limits of agreement (Figure 5-4) based on the study distribution of Doppler measurements. 
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 Colin vs. Doppler Agreement 
The between-method comparison resulted in an intra-class correlation coefficient = 0.44 and 
linear correlation coefficient = 0.64 (Figure 5-5).  The differences between Colin ABI and 
Doppler ABI measurements followed a roughly normal distribution, although there was one 
significant outlier (difference of 0.38).  Doppler ABI tended to be higher than Colin ABI; 
according to the equivalence test described in the power and sample size section, we do not have 
sufficient evidence to conclude that the methods are equivalent (mean difference = 0.08, 95% CI: 
0.05-0.11, p=0.105).  The mean absolute difference between methods was 0.09 (SD=0.09), and 
26 of 40 participants (65.0%) had an absolute difference ≤ 0.10 between the respective means for 
the two methods.  Only one of the 40 participants fell outside the Bland-Altman limits of 
agreement (Figure 5-6) calculated based on the distribution of our study data; however, it must 
be noted that the limits of agreement are wider for between-method comparison than within-
method comparisons. 
 
We can also evaluate agreement using categories of low, normal, and high ABI defined by AHA 
guidelines described in the introduction (Table 5-6).  32 of 40 participants are classified 
“normal” by each method, and one participant is deemed “high” by both methods, yielding 
categorical agreement for 33 of 40 subjects.  However, the kappa statistic is only 0.17, indicative 
of poor agreement between the methods.  Most of the discordance stemmed from 6 participants 
classified as “high” by Doppler and “normal” by Colin, while only one was classified “low” by 
Colin and “normal” by Doppler.  The lack of any participants with low ABI by both methods 
makes it impractical to calculate a kappa statistic for detection of low ABI vs. non-low ABI. 
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 Sensitivity Analyses 
We also performed analyses stratified by caffeine intake and exercise prior to study visit to see if 
results were consistent (Table 5-7).  The correlation between Colin measurements was slightly 
higher for those who abstained from caffeine compared to those who consumed (r=0.90 for 
abstainers vs. r=0.73 for consumers, p=0.13), while the opposite was true for Doppler 
measurements (r=0.86 for abstainers vs. r=0.95 for consumers, p=0.13), although neither of these 
differences were statistically significant.  In the analyses stratified by exercise (Table 5-8), the 
correlation coefficient between Colin measurements was lower for those who abstained 
compared to those who exercised (r=0.64 vs. r=0.91, p=0.03), while there was little difference 
between correlations for Doppler measurements (r=0.90 vs. r=0.95, p=0.30).   Mean absolute 
differences were distributed similarly for each comparison, suggesting that caffeine intake and 
exercise did not significantly alter reproducibility of ABI measurements in this study; it should 
be noted that these are based on small groups, so power to detect such differences is limited. 
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 5.5 DISCUSSION 
We evaluated the reproducibility of ABI measurements taken using both the Colin VP-1000 
oscillometric device and the Doppler method at the University of Pittsburgh’s Epidemiology 
URL.  The Doppler ABI measurements had excellent reproducibility, with an intra-class 
correlation > 0.9 and 95% of participants with an absolute difference less than 0.10 between the 
two Doppler measurements.  Reproducibility of Colin ABI was not quite as strong, but still 
showed reasonable agreement with a intra-class correlation > 0.8 and 90% of participants having 
an absolute difference less than 0.10 between repeated Colin measurements. 
 
There was significant evidence of nonequivalence between methods; ABI measurements taken 
with Doppler were generally higher than Colin measurements on the same participant (mean 
difference=0.08), and 14 of 40 (35%) participants had mean Doppler ABI at least 0.10 greater 
than their mean Colin ABI, large enough to be clinically significant.  Since brachial pressures 
were distributed similarly between methods, it appears that the differences in ABI were primarily 
driven by the differences in ankle pressures. 
 
One possible explanation is the sequence in which the measurements were taken.  Recall that the 
first ABI measurement was taken using the Colin, followed by the first sequence of Doppler 
measurements, then the Colin again, and finally the Doppler again.  If systemic pressure rose 
with each measurement, one would expect higher ankle pressures with the Doppler.  However, 
this seems unlikely because ankle pressures from the second Colin measurement were 
significantly lower than both the Doppler measurement that came before it and after it. 
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 A second possible explanation is that the time required to take four separate Doppler pressures 
may lead to an inaccurate evaluation of inter-site blood pressure ratios; changes in systemic 
pressure may occur during the time required to take four separate measurements needed to 
calculate ABI.167 In this study, recall that Doppler measurements were taken in the following 
sequence: left brachial, right brachial, left ankle, right ankle.  This process can take several 
minutes, during which the patient may experience changes in systemic pressure.  It is also 
possible that Doppler ABI is prone to observer error if there are consistent differences in the time 
taken to hear the flow signal and record the pressure for the arm compared to the ankle. 
 
A third possible explanation is the difference between the Colin and Doppler measurement sites 
used to obtain the ankle pressures.  The pressure cuff is placed slightly more distally for ankle 
pressure measurement with a Doppler probe than it is for measurement with the Colin; therefore, 
it is possible that ankle pressures tend to be higher using the Doppler because of greater distal 
amplification of systolic BP generated by pressure-wave reflections within the arterial tree.168 
Furthermore, recall that the ankle pressure can be taken at either the dorsalis pedis (DP) or the 
posterior tibial (PT) arteries; since the PT pulse is missing or impossible to locate in 
approximately 10-20% of the population, the DP is commonly used for Doppler ankle pressure 
measurements, and was the measurement site used in this study.  However, the Colin always 
measures ankle pressure using the PT pulse.  There is no published evidence that the DP ankle 
pressure differs systematically from the PT ankle pressure, but it is possible that the difference in 
measurement site could explain some of the systematic difference, noting that our results showed 
Doppler ankle pressures that tended to be higher than Colin ankle pressures.   
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 While the Colin ABI tended to be lower than the Doppler in our study, the Colin retains possible 
utility as a PAD screening tool if it classifies participants in the same category of low (ABI≤0.9), 
normal (0.9<ABI≤1.3), and high (ABI>1.3) as the Doppler method.  33 participants had an ABI 
in the “normal” range according to the Doppler, and 32 of these were also identified as “normal” 
by their Colin ABI; however, since there were no participants with low ABI according to the 
Doppler, we cannot appropriately evaluate the sensitivity of the Colin as a PAD screening tool.  
Our study would require a larger sample with more participants outside the “normal” range, 
especially in the “low” range since that is indicative of peripheral arterial disease. 
 
Comparison to Previous Studies 
Within the last three years, several studies have evaluated validity of various oscillometric 
devices against the Doppler method.  A 2012 meta-analysis (18) pooled the results of eighteen 
studies (N=3290) comparing oscillometric ABI measurements to the Doppler method and found 
an average difference of 0.020 ± 0.018, indicating that oscillometric ABI tended to be higher 
than Doppler, although this difference was not statistically significant (p=0.28).  This conflicts 
with our findings that the Doppler measurements were higher than the Colin oscillometric 
measurements. The meta-analysis also reports a pooled linear correlation coefficient of 0.71 
between Doppler ABI and oscillometric ABI, slightly greater than the linear correlation of 0.64 
observed in our study.  It should be noted that there was substantial heterogeneity between 
studies included in the meta-analysis; possible explanations include the use of different 
oscillometric devices, variation between study protocols, and differences in study populations.   
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 Among the eighteen studies included in the meta-analysis mentioned above, eleven different 
oscillometric devices were used, and only two studies included in the pooled results used the 
Colin device (two other studies have compared ankle blood pressures measured with the Colin to 
those measured with Doppler, but are not included in the meta-analysis due to lack of ABI data).  
The four studies comparing Colin and Doppler measurements are briefly summarized below. 
 
Cortez-Cooper (2003)121 compared ankle blood pressure measurements taken with the Colin to 
those taken with Doppler in 52 participants. This study showed strong linear correlation between 
ankle pressure measurements (r=0.95) taken with Colin versus Doppler, higher than the 
correlation between Colin and Doppler ankle pressures observed in the present study (r=0.8).  
Ankle pressures measured with the Doppler were slightly higher than the Colin ankle pressures, 
although the mean difference between methods (2.2 mm Hg) was smaller than that observed in 
our study (8.0 mm Hg).  Direct comparison with our results is difficult because it is not clear 
whether the patient or the limb was the unit of analysis, nor is it clear exactly how the methods 
are compared (i.e. average of the two limbs; lower of the two limbs).  Also, since this study 
reported only ankle pressures, we cannot evaluate how its results compare to our ABI results. 
 
Nukumizu (2007)122 compared Doppler ankle pressures to Colin ankle pressures in 168 
participants from a vascular clinic, all of whom had angiographically confirmed peripheral 
arterial disease (n=146) or abdominal aortic aneurysm (n=22).  The Colin ankle pressures were 
slightly higher than Doppler ankle pressures, on average; the authors reported the ratios of Colin 
pressure divided by Doppler pressure for each participant, and noted that 135 of 168 (80%) 
participants had a Colin ankle pressure within 10 percent of their Doppler ankle pressure.  
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 Notably, the agreement was significantly worse for PAD patients than non-PAD patients, 
suggesting that the Colin may be less reliable in patients with PAD.  One limitation which might 
influence these results: the study methods do not mention any rest period between Doppler 
measurement and Colin measurement.  In the absence of a rest period between measurements, 
these results may be influenced by artificially elevated readings for Colin ankle pressure. 
 
Pan (2007)123 performed a population-based study analyzing data from 946 participants in 
several rural villages south of Shanghai.  The Doppler ABI measurements were slightly higher 
than the Colin ABI measurements, a similar trend to that observed in our study, although the 
between-measurement differences were smaller than those observed in our study (mean 
difference=0.03 for Pan et al vs. 0.08 in our study).  Pan et al also noted that the gap between 
Doppler ABI and Colin ABI increased at higher values of the ABI (greater than 1.2).  One 
limitation worth noting is that this study only performed a Doppler measurement at the right side, 
so they discarded Colin measurements obtained at the left side. 
 
In the most recent published study comparing Colin ABI vs. Doppler ABI, Richart (2009)124 
measured ABI in 105 participants from a rural area near Flanders, Belgium.  In this study, 
Doppler ABI tended to be slightly greater than Colin ABI, concordant with our study results; 
however, Richart et al also found that the Colin had better reproducibility than the Doppler, 
whereas we found slightly better reproducibility using the Doppler method.  This study also 
performed a Doppler measurement only at the right arm and ankle, discarding the Colin data 
obtained from the left side.   
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 The results from the four prior studies comparing Colin and Doppler ankle pressures and/or ABI 
combined with the present study can be synthesized into the following statements:  
 
1) The Colin has displayed reasonable agreement with Doppler in participants with normal ABI.  
2) The Colin may be less accurate for patients with extreme values of ABI (both low and high); 
in particular, it may provide falsely normal values for patients with very low values of ABI. 
3) No consistent pattern has emerged to establish a directional relationship between Colin and 
Doppler measurements; there is somewhat weak evidence that the Doppler tends to report 
slightly higher ankle pressures and/or ABI than the Colin, but this could be accounted for by 
differences in study populations and protocol. 
4) No consistent pattern has shown that either method has definitively better reproducibility.  
Richart et al reported that the Colin had slightly better reproducibility than Doppler ABI, 
while our results showed better reproducibility with the Doppler. 
5) There is no significant evidence that smoking, exercise, or caffeine intake affects the 
reproducibility of ABI measurements taken in the same visit.  However, these behaviors may 
affect the measurement between visits. 
 
Other Oscillometric Devices 
Most studies using other oscillometric devices have found that oscillometric ABI was slightly 
greater than Doppler ABI or that there was no difference between methods (18).  Other than the 
differences in devices, results may vary due to differences in measurement protocol and study 
populations (patients referred to vascular laboratories, inclusion of participants with PAD).  For 
example, Beckman (2006)169 found that ABI measured by the Cas 740 oscillometric device 
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 tended to be higher than Doppler, while our study showed the opposite. However, all participants 
in this study were referred to the laboratory for evaluation of PAD; since we have noted that the 
Colin is less reliable than the Doppler for participants with extreme values of ABI, it is possible 
that this pattern of higher ABI with the Cas 740 oscillometric device is driven by the inclusion of 
participants with PAD, similar to that described by Nukumizu et al. 
 
Strengths and Limitations 
Our findings must be considered in appropriate context of our study’s strengths and limitations.  
The principal investigator trained both of the observers that performed ABI measurements during 
the study.  All four of the ABI measurements on any single participant were performed by the 
same observer, and all were performed in a single office visit, eliminating potential concerns due 
to interobserver variability and day-to-day variation in blood pressure. 
 
This study also has a few important limitations.  Although taking all four measurements in a 
single visit eliminates the potential for day-to-day variation in pressures, the Colin and Doppler 
measurements were always taken in the same sequence, allowing the possibility that performing 
one measurement first influences the readings in subsequent measurements.  A rest period was 
implemented between each measurement, but the sequence still may have an effect.  This study 
includes only 40 participants, limiting our ability to perform subgroup analyses and sensitivity 
analyses, and our participants comprised a convenience sample of primarily healthy volunteers.  
With so few participants demonstrating abnormal ABI values, the generalizability of these 
findings is likely limited to participants with normal ABI.   
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 It should be noted that we reported our primary results using the patient as the unit of analysis 
rather than the limb; we followed this convention because most epidemiological studies consider 
the lower of each participant’s left/right ABI as a marker of cardiovascular risk.  However, we 
performed limb-specific analyses (data not shown) that were consistent with the patient-level 
results, showing similar reproducibility within methods and agreement between methods. 
 
Public Health Implications 
The ABI is used primarily as a screening tool for PAD in high-risk patients.  However, as one of 
the least expensive and least invasive markers of systemic atherosclerosis, the ABI could be very 
useful for CVD risk assessment in primary care.  Both low ABI and high ABI are known to be 
predictive of cardiovascular events, and a 2008 meta-analysis showed that ABI provided 
additional predictive value when combined with the Framingham Risk Score.170 Changes in ABI 
over time also provide predictive value; patients with significant decreases in ABI over time are 
proven to have increased risk for cardiovascular morbidity and mortality.171 These results 
suggest that judicious use of the ABI in primary care settings has potential to improve public 
cardiovascular health.172  
 
Despite this potential, the ABI remains underutilized in primary care.28  According to practicing 
physicians, one of the greatest barriers to office-based ABI measurement is the time required for 
testing.173 The Colin VP-1000 has potential to mitigate concerns about time by allowing 
simultaneous pressure measurements of all four limbs; in addition, obtaining an ABI with the 
Colin also requires little specialized training and could be performed by an office assistant.   
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 5.6 CONCLUSION 
In this report, we present evidence that the Colin VP-1000 oscillometric device is capable of 
measuring ABI with a moderate level of reproducibility; however, agreement between the Colin 
ABI and the gold-standard Doppler method is less than ideal.  Colin ABI measurements were 
consistently higher than Doppler ABI measurements performed on the same patient, and there is 
not significant evidence of equivalence between methods.  While measuring ABI with the Colin 
could prove more cost-effective and practical than the Doppler method because it is faster to 
perform and requires less training, our study results do not support the replacement of Doppler 
ABI measurements with Colin ABI measurements in a clinical setting. 
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 5.7 TABLES AND FIGURES 
Table 5-1. Required Sample Sizes to Achieve 80% Power and 90% Power 
 
Power 
80% 90% 
Assumed 
Correlation 
Between 
Measurements 
0.2 33 127 
0.4 25 31 
0.6 17 22 
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Table 5-2. Baseline Characteristics of Study Participants 
Characteristic N=40 
Age, years 35.4 ± 11.9 
Gender (Female) 70.0% 
Race  
   White 82.5% 
   Black 7.5% 
   Asian 10.0% 
Height, inches 66.8 ± 3.6 
Weight, pounds 161.2 ± 47.2 
BMI, kg/m2 25.3 ± 6.6 
   BMI “Normal” (18.0-24.9) 65.0% 
   BMI “Overweight” (25.0-29.9) 22.5% 
   BMI “Obese” (>30.0) 12.5% 
Self-Reported Diabetes 5.0% 
Self-Reported Hypertension 10.0% 
Self-Reported Hypercholesterolemia 12.5% 
Smoke within 12 hours of visit 0.0% 
Caffeine within 12 hours of visit 62.5% 
Exercise within 12 hours of visit 40.0% 
*Variables are presented as mean ± SD unless denoted as a percentage 
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Table 5-3. Descriptive Statistics of Blood Pressure Measurements 
  Left Right 
Colin #1 Brachial 114.8 ± 12.9  115.9 ± 13.0  
Ankle 127.2 ± 16.5  126.1 ± 17.2  
Doppler #1 Brachial 115.6 ± 13.8 114.8 ± 13.9  
Ankle 135.5 ± 19.2 135.0 ± 18.8  
Colin #2 Brachial 114.9 ± 12.2  116.7 ± 12.7 
Ankle 129.7 ± 18.1 128.9 ± 18.1 
Doppler #2 Brachial 115.8 ± 14.2 114.7 ± 13.3  
Ankle 136.4 ± 18.9 136.2 ± 18.5  
All statistics reported as Mean ± SD 
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Table 5-4. Descriptive Statistics of ABI Measurements 
 Mean ± SD Median (IQR) 
Colin #1 1.05 ± 0.11 1.06 (0.98-1.13) 
Doppler #1 1.14 ± 0.13 1.12 (1.04-1.21) 
Colin #2 1.08 ± 0.09 1.07 (1.03-1.13) 
Doppler #2 1.15 ± 0.12 1.12 (1.07-1.21) 
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Table 5-5. Intra-Class Correlations, Linear Correlations, and Mean Absolute Differences 
for Primary Comparisons Reported in Text 
 Intra-Class Correlation 
Colin ABI #1 vs Colin ABI #2 0.77 
Doppler ABI #1 vs Doppler ABI #2 0.91 
Mean Colin ABI vs Mean Doppler ABI 0.44 
 Linear Correlation 
Colin ABI #1 vs Colin ABI #2 0.81 
Doppler ABI #1 vs Doppler ABI #2 0.92 
Mean Colin ABI vs Mean Doppler ABI 0.64 
 Mean Absolute Difference 
Colin ABI #1 vs Colin ABI #2 0.06 ± 0.04 
Doppler ABI #1 vs Doppler ABI #2 0.04 ± 0.04 
Mean Colin ABI vs Mean Doppler ABI 0.09 ± 0.09 
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Table 5-6. Between-Method Agreement by ABI Category 
 Colin ABI ≤ 0.9 0.9 < Colin ABI ≤ 1.3 Colin ABI > 1.3 
Doppler ABI ≤ 0.9 0 0 0 
0.9 < Doppler ABI ≤ 1.3 1 32 0 
Doppler ABI > 1.3 0 6 1 
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 Table 5-7. Stratified By Caffeine Intake 
 No Caffeine 
(n=15) 
Caffeine 
(n=25) 
 Intra-Class Correlation 
Colin ABI #1 vs Colin ABI #2 0.83 0.71 
Doppler ABI #1 vs Doppler ABI #2 0.86 0.94 
Mean Colin ABI vs Mean Doppler ABI 0.71 0.55 
 Linear Correlation 
Colin ABI #1 vs Colin ABI #2 0.90 0.73 
Doppler ABI #1 vs Doppler ABI #2 0.86 0.95 
Mean Colin ABI vs Mean Doppler ABI 0.74 0.57 
 Mean Absolute Difference 
Colin ABI #1 vs Colin ABI #2 0.06 ± 0.04 0.06 ± 0.04 
Doppler ABI #1 vs Doppler ABI #2 0.06 ± 0.04 0.03 ± 0.03 
Mean Colin ABI vs Mean Doppler ABI 0.09 ± 0.07 0.09 ± 0.09 
 
121 
  
Table 5-8. Stratified by Exercise Prior to Study Visit 
 No Exercise 
(n=24) 
Exercise 
(n=16) 
 Intra-Class Correlation 
Colin ABI #1 vs Colin ABI #2 0.61 0.86 
Doppler ABI #1 vs Doppler ABI #2 0.90 0.95 
Mean Colin ABI vs Mean Doppler ABI 0.45 0.75 
 Linear Correlation 
Colin ABI #1 vs Colin ABI #2 0.64 0.91 
Doppler ABI #1 vs Doppler ABI #2 0.90 0.95 
Mean Colin ABI vs Mean Doppler ABI 0.47 0.78 
 Mean Absolute Difference 
Colin ABI #1 vs Colin ABI #2 0.05 ± 0.04 0.06 ± 0.04 
Doppler ABI #1 vs Doppler ABI #2 0.04 ± 0.04 0.04 ± 0.03 
Mean Colin ABI vs Mean Doppler ABI 0.09 ± 0.09 0.09 ± 0.07 
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Figure 5-1. Scatterplot of Colin ABI Measurement #1 vs. Colin ABI Measurement #2 
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Figure 5-2. Bland-Altman Plot of Difference in Colin ABI Measurements vs. Mean Colin 
ABI 
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Figure 5-3. Scatterplot of Doppler ABI Measurement #1 vs. Doppler ABI Measurement #2 
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Figure 5-4. Bland-Altman Plot of Difference in Doppler ABI Measurements vs. Mean 
Doppler ABI 
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Figure 5-5. Scatterplot of Mean Doppler ABI vs. Mean Colin ABI 
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Figure 5-6. Bland-Altman Plot of Between-Method Differences vs. Mean Overall ABI
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 6.0  SUMMARY OF FINDINGS 
The first manuscript reports the incidence of peripheral arterial disease (PAD) in the Bypass 
Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.  Approximately 20% of 
the 1,479 BARI 2D patients free from PAD at baseline were diagnosed with new PAD (defined 
as an ankle-brachial index ≤ 0.9 with a decrease of at least 0.1 from the baseline measurement) 
or another lower extremity event indicative of advancing PAD (lower extremity 
revascularization and/or lower extremity amputation) over an average 4.6 years of follow-up.  
The incidence of PAD and other lower extremity outcomes was significantly lower in patients 
assigned to an insulin sensitizing strategy than the incidence among those assigned to an insulin 
providing strategy (16.9% vs. 24.1%, p<0.001).  Therefore, the BARI 2D results suggest that 
treatment of type 2 diabetes primarily using insulin sensitizing agents (metformin and/or 
thiazolidinediones) may result in lower incidence of PAD than treatment with a glycemic control 
strategy using insulin providing agents.  Theoretically, this result implies that treatment with 
insulin sensitizing medications may slow progression of systemic atherosclerosis in patients with 
type 2 diabetes and advanced coronary artery disease.  The effect of assigned glycemic control 
strategy remained statistically significant in a Cox proportional-hazards model after adjusting for 
in-trial HbA1c, suggesting that the insulin sensitizing medications may have conferred a benefit 
through a pathway besides improved glycemic control.  Possible alternative pathways by which 
insulin sensitizing medications may achieve this include their effects on the interrelated 
processes of inflammation, coagulation, and fibrinolysis. 
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 The second manuscript builds upon the first by examining a number of potential risk factors for 
PAD in the BARI 2D trial, first within the entire study cohort and then within the context of the 
two glycemic control strategies.  The analyses included traditional cardiovascular risk factors 
such as body mass index, lipids, blood pressure, and Hb1Ac as well as novel risk factors 
indicative of inflammation, coagulation, and fibrinolysis such as C-reactive protein (CRP), 
fibrinogen, D-dimer, tissue-type plasminogen activator (t-PA), and plasminogen activator 
inhibitor-1 (PAI-1).  Cox proportional-hazards models were used to establish independent 
associations between the selected baseline risk factors and PAD (while adjusting for age, sex, 
race, and smoking status) and then multivariable models were used to see which baseline risk 
factors provided the greatest predictive value.  Systolic blood pressure, pulse pressure, HbA1c, 
albumin-creatinine ratio (ACR), and CRP showed significant associations with PAD in separate 
models.  When assessed using a multivariate model created using a forward selection algorithm, 
three variables (HbA1c, ACR, and D-dimer) showed significant associations with PAD. 
 
A second set of analyses using each risk factor as a time-varying covariate was performed to 
assess how longitudinal changes in each risk factor were associated with risk of PAD.  These 
analyses were stratified by assigned glycemic control strategy because of the possibility that the 
treatment strategy could have influenced the value of the risk factors over time as well as the 
outcome.  Notably, among patients assigned to the insulin providing strategy, only HbA1c and 
ACR were significantly associated with lower extremity outcomes, while among patients 
assigned to insulin sensitizing strategy a host of traditional cardiovascular risk factors (LDL, 
HDL, systolic blood pressure, pulse pressure) as well as D-dimer were significant in models that 
adjusted for age, sex, race, and smoking status.   
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 In multivariable models, change in HbA1c was the only significant predictor of outcome in the 
patients assigned to insulin providing strategy, while D-dimer was the most significant predictor 
of outcome in the patients assigned to insulin sensitizing strategy.  If D-dimer were not included 
as a candidate variable in this analysis, then fibrinogen would have entered the model in our 
forward selection algorithm (only for the analysis of patients assigned to insulin sensitizing 
strategy).  If neither D-dimer nor fibrinogen were included as candidate variables, then CRP 
would have entered the model (again, only for patients assigned to insulin sensitizing strategy).  
This is noteworthy because the markers of inflammation, coagulation, and fibrinolysis were 
associated with lower extremity outcomes among patients treated with insulin sensitizing 
medications, but this was not the case for patients treated with insulin providing medications, 
thereby suggesting that these medications may have a differential effect on these processes and 
subsequently on the development of atherosclerosis in patients with type 2 diabetes. 
 
The third manuscript reports the results of a data collection project evaluating reproducibility and 
reliability of two different methods for measuring ankle-brachial index: 1) the Colin VP-1000 
oscillometric device and 2) the current gold-standard method involving a Doppler probe.  Our 
results showed excellent reproducibility for ABI measured with the Doppler, while the Colin 
oscillometric device showed moderately good reproducibility but did not match the excellent 
reproducibility achieved with Doppler.  Agreement between Colin and Doppler was somewhat 
poor; therefore, based upon these results, we would not likely recommend the use of Colin ABI 
measurements to diagnose peripheral arterial disease in clinical settings. 
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 7.0  PUBLIC HEALTH SIGNIFICANCE 
The public health significance of this research is primarily derived from the first two manuscripts 
regarding the incidence of peripheral arterial disease in patients with type 2 diabetes.  The first 
manuscript suggests that insulin sensitizing medications (metformin and/or thiazolidinediones) 
may reduce the incidence of peripheral arterial disease in patients with type 2 diabetes and stable 
coronary artery disease; this can be interpreted as evidence that an insulin sensitizing strategy 
reduces the progression of systemic atherosclerosis.  The second manuscript builds upon the first 
by demonstrating that longitudinal changes in biomarkers of inflammation, coagulation, and 
fibrinolysis are predictive of incident peripheral arterial disease in these patients when treated 
with insulin sensitizing medications, providing a possible mechanistic insight to how these 
medications affect the progression of atherosclerosis differently than treatment with insulin 
providing medications.  These manuscripts have implications for both 1) clinicians treating 
patients with diabetes and 2) bench-science researchers investigating the mechanisms that 
influence the development of atherosclerosis. 
 
As published previously, all-cause mortality and cardiovascular mortality was comparable 
between the assigned glycemic control arms in BARI 2D. 127  However, the insulin sensitizing 
strategy did demonstrate some noteworthy physiological benefits, specifically changes in 
biomarker profiles indicative of decreased insulin resistance, an altered balance between 
thrombosis and fibrinolysis favoring fibrinolysis, and diminished intensity of the systemic 
inflammatory state.98  It was recognized a priori that an association of differences in biomarker 
profiles with clinical outcomes might not be evident because the ancillary study of CRP, 
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 fibrinogen, and D-dimer was not powered to delineate effects on outcomes.  Furthermore, since a 
systemic inflammatory state and impaired fibrinolysis are thought to affect clinical outcomes 
over prolonged intervals, and this study was carried out in a population that had quite advanced 
coronary disease upon study entry, it is unsurprising that beneficial effects of insulin sensitizing 
therapy on these biomarkers did not translate into significantly better mortality outcomes during 
BARI 2D follow-up. 
 
The research contained in this dissertation provides further ammunition supporting the benefits 
of insulin sensitizing therapy and creates at least one fascinating hypothesis.  Peripheral arterial 
disease is one of the foremost markers of “subclinical” atherosclerosis and, as detailed in this 
document’s introduction, is known to be associated with cardiovascular mortality and all-cause 
mortality.  Therefore, first manuscript’s finding that an insulin sensitizing strategy may reduce 
the risk of peripheral arterial disease carries the implication that these drugs may reduce the 
progression of atherosclerosis; therefore, it is possible that if they are used earlier in the disease 
process and/or in a population with less disease burden, they might reduce the development of 
coronary atherosclerosis before disease becomes too advanced to observe a clinical benefit.  
Mechanistically, if the effects of insulin sensitizing medications on developing atherosclerosis 
occur by their effects on inflammation, coagulation, and fibrinolysis - processes that are not 
thought to affect clinical outcomes in the short term, but rather over a prolonged interval - then it 
is possible that these medications would result in cardiovascular risk reduction in a study of 
patients with less advanced disease at study entry and longer follow-up. 
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 Making this argument even more compelling is the second manuscript’s finding that longitudinal 
changes in biomarkers such as CRP, fibrinogen, and D-dimer were more closely associated with 
PAD outcomes in the patients assigned to treatment with insulin sensitizing therapy.  Therefore, 
it is possible that patients treated with insulin sensitizing medications that experienced reductions 
in the systemic inflammatory state and improved fibrinolysis were protected from the continuing 
development of atherosclerosis, but the patients treated with insulin sensitizers that did not 
experience these benefits were more prone to the continued development of atherosclerosis 
(manifesting itself as an incident case of PAD).  Further research should be carried out to 
determine whether insulin sensitizing medications do, in fact, affect the development of 
atherosclerosis through these specific pathways, particularly if this information can be leveraged 
to create new therapeutic targets. 
 
All of the arguments thus far point to a benefit of insulin sensitizing medications; it should be 
noted that the American Diabetes Association (ADA) 2013 Clinical Practice Recommendations 
recommend an insulin sensitizing drug, metformin, as the first-line therapy for patients with 
diabetes.174  Metformin was the most commonly used insulin sensitizing medication in the BARI 
2D trial, with over 70% of patients assigned to insulin sensitizing therapy taking metformin at 
their three-year study visit.  While the “insulin providing versus insulin sensitizing” design used 
in the BARI 2D trial is not well-suited to analyze specific medications because of the complex 
nature of the glycemic control strategy employed in BARI 2D, it may be reasonably inferred that 
the benefits of insulin sensitizing medications on peripheral arterial disease outcomes are at least 
in part due to the use of metformin.  Therefore, our research supports the current guidelines by 
demonstrating an as-yet-unidentified benefit of insulin sensitizing therapy. 
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 The ADA 2013 Clinical Practice Recommendations also offer comprehensive guidelines for 
cardiovascular risk reduction in patients with type 2 diabetes as follows: 
 People with diabetes and hypertension should be treated to a systolic blood pressure goal 
of < 140 mm Hg; lower systolic blood pressure targets may be appropriate for certain 
individuals if it can be achieved without undue treatment burden 
 LDL-cholesterol targeted statin therapy remains the preferred strategy, targeting an LDL 
level of less than 100 mg/dL in individuals without overt CVD and an LDL level of less 
than 70 mg/dL in individuals with overt CVD 
 Statin therapy should be added to lifestyle therapy, regardless of baseline lipid levels, for 
diabetic patients that meet one or more of the following criteria: 
o Family history of CVD 
o Hypertension 
o Smoking 
o Albuminuria 
 Aspirin therapy for patients with type 2 diabetes at an increased cardiovascular risk (same 
risk factors listed above); clopidogrel may also be considered for those with an aspirin 
allergy or in combination with aspirin for especially high-risk patients 
 All patients are advised not to smoke or use tobacco products 
Our findings do not have any specific bearing on the aforementioned recommendations, which 
are similar to those presented in Figure 1-8 regarding CVD risk reduction for patients with 
peripheral arterial disease.  Thus, we conclude that the first two manuscripts support current 
practice guidelines by reinforcing the notion that all patients with type 2 diabetes should first be 
treated using insulin sensitizing medications when practical. 
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 The third manuscript leaves the question of insulin sensitizing medications’ effect on 
atherosclerosis to ask a simpler question regarding the diagnosis of peripheral arterial disease: 
does the Colin VP-1000 oscillometric device offer potential to measure the ankle-brachial index 
(the principal diagnostic tool for PAD) with greater reproducibility than the current gold-
standard technique using a Doppler probe? 
 
According to our data, the answer is no.  The reproducibility of ABI measurements taken using 
the Colin VP-1000 was inferior to reproducibility of ABI measurements taken using a traditional 
Doppler probe in all respects.  Agreement between the two methods was mediocre at best, 
certainly less than that necessary to declare the Colin VP-1000 equivalent to the Doppler ABI.  
Therefore, based on the superior reproducibility displayed by Doppler and the lack of 
equivalence between Colin-measured ABI and Doppler-measured ABI, we cannot recommend 
the Colin VP-1000 oscillometric device as a replacement for Doppler-measured ABI in research 
settings or clinical settings. 
 
In 2012, the American Heart Association issued a Scientific Statement on the measurement and 
interpretation of the ankle-brachial index in response to a lack of standards for measurement and 
calculation of ABI.157  The AHA Scientific Statement notes that the correlation between 
Doppler-derived and oscillometric-determined ankle pressures and ABIs has been “generally 
acceptable in most studies with 1 exception” but still recommends that the Doppler method is the 
most reliable method to determine ABI and should be considered the gold-standard method.  Our 
results support this statement, and therefore are in agreement with current AHA guidelines. 
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 In summary, the research contained in this dissertation: 
 
1. Documents the incidence of peripheral arterial disease in a defined population from a 
randomized controlled trial of patients with type 2 diabetes and coronary artery disease, 
illustrating that the atherosclerotic process continues even in those treated aggressively 
2. Provides evidence of an as-yet-unidentified benefit of insulin sensitizing medications, the 
reduction in risk of incident peripheral arterial disease, thereby supporting current 
guidelines regarding the use of insulin sensitizing medications as the first-line therapy for 
treatment of type 2 diabetes mellitus 
3. Suggests a potential mechanistic pathway through which insulin sensitizing medications 
may affect the progression of atherosclerosis, which can be studied to see if the pathways 
involved have any promise as therapeutic targets and/or can be better used to identify 
those at high risk of developing atherosclerotic plaques 
4. Evaluates the reliability and reproducibility of two techniques that can be used to 
diagnose peripheral arterial disease and provides evidence that the current gold-standard 
method, using a Doppler probe, should remain the principal technique for evaluation of 
ABI in research settings and, likely, in clinical settings as well 
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 APPENDIX A 
Doppler ABI Testing Instructions 
 
1. Patient Preparation 
1) Bring the patient into a quiet room at normal room temperature (21-23 C). 
2) Instruct the patient to remove their socks and shoes. 
3) Instruct the patient to lie in a supine position with the ankles at heart level and the feet 
arranged so that the toes are pointed towards the ceiling. 
4) Ascertain the appropriate cuff size for each limb  
5) Place pressure cuffs approximately 3 cm above the cubital fossa on the arms. 
6) Place pressure cuffs approximately 3 cm above the medial malleoulus on the ankle. 
7) Allow the patient to remain at rest in the quiet room for 5 minutes. 
 
2. Answer any questions and explain the test using the following sample participant script: 
 
This test will take approximately 5 minutes during which time multiple blood pressures will be 
taken on each arm and ankle.  While the test is being performed we ask you to hold still, remain 
quiet and not fall asleep. 
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 3. Brachial Pressure Measurements 
1) Locate brachial pulse on the right arm 
2) Apply small mound of ultrasound transmission gel to the pulse site 
3) Place the tip of the Doppler probe on top of the gel at a 45-degree angle 
4) Adjust the Doppler probe to obtain the best audible pulse signal 
5) Inflate the pressure cuff 20 mm Hg beyond the last audible signal 
6) Deflate cuff (2 mm Hg/sec) until first audible signal (systolic pressure only) 
7) Record the pressure at first audible signal 
8) Repeat steps (1-7) using the left arm 
 
4. Ankle Pressure Measurements 
1) Locate dorsalis pedis (DP) pulse in the right ankle 
2) Apply small mound of ultrasound transmission gel to the pulse site 
3) Place the tip of the Doppler probe on top of the gel at a 45-degree angle 
4) Adjust the Doppler probe to obtain the best audible pulse signal 
5) Inflate the pressure cuff 20 mm Hg beyond the last audible signal* 
6) Deflate cuff (2 mm Hg/sec) until first audible signal (systolic pressure only) 
7) Record the pressure at first audible signal (*note: if the artery cannot be occluded 230 
mm Hg, ankle pressure should be recorded as “non-compressible”) 
8) Repeat steps (1-7) above using the left ankle 
136 
 APPENDIX B 
Colin VP 1000 Testing Instructions 
 
1. Answer any questions and explain the test using the following sample participant script: 
 
This test will take approximately 5 minutes during which time multiple blood pressures will be 
taken on each arm and ankle.  While the test is being performed we ask you to hold still, remain 
quiet and not fall asleep.  
 
2. Anthropometric Measurements: Five anthropometric measures are required on the RIGHT 
side prior to the Colin test.  All measurements must be taken with a steel measuring tape and 
recorded in centimeters on the Colin worksheet.  They are described on the following page in 
sequence: 
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1) Carotid to suprasternal notch: 
Measure the distance from the sampling site of the right carotid artery to the 
suprasternal notch. 
2) Suprasternal notch to umbilicus: 
Measure from the suprasternal notch to the inferior (lower) edge of the umbilicus. 
3) Umbilicus to common femoral: 
Measure from the inferior (lower) edge of the umbilicus to the sampling site of 
the right common femoral artery. 
4) Femoral to ankle: 
Measure from the sampling site of the right common femoral artery to the medial 
malleolus. 
5) Suprasternal notch to antecubital fossa: 
Measure from the suprasternal notch to the dot placed at the antecubital fossa 
6) Calculate Lcf measurement = (#2) + (#3) - (#1) 
 
3. To enter subject information on the Colin ID Input Screen rotate the jog dial to the desired 
digit.  When the digit desired is displayed in the blue box, depress the jog dial to select.  The 
selected digit will then appear the ID box.  Repeat the previous step to choose all digits.  If an 
error is made, select the F1 (correction) button and the last digit entered will be deleted.  Pressing 
New ID will delete the entire ID. When ready, press F3 to confirm.  The ID number will appear 
in the blue box at the top left-hand corner of the screen. 
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 4. Participant information is entered into the next screen.   
 
1) The sex (gender) field is first and defaults to male.  If the participant is a female, depress 
the jog dial and the screen will be highlighted in blue.  Rotate the dial to select female 
and depress the jog dial again.   
2) Rotate the jog dial to move to the next field; use the jog dial to enter the participant’s 
height.   
3) Use the jog dial to bypass the Lcf* field (used only with carotid-femoral sensors). 
4) Next enter participant’s weight and birth date.  
5) The fields to the right of the participant information are already entered.  They should be 
completed as follows and never changed: 
 
Meas. Part:  Both Arms + Legs 
Pressurized Right Ankle: AUTO 
Pressurized Left Ankle: AUTO 
Measurement Times: 1 
Wait Time: 10 sec. 
Tonometry:  
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 5. Choose a cuff appropriate for the patient by selecting the correct size (determined by the 
patient’s arm circumference).  
 
 Cuff Size (cm) 
Limb Circumference (cm) Bladder 
Width 
Bladder 
Length 
16-21 8 21 
22-26 10 24 
27-34 13 30 
35-44 16 38 
45-52 20 42 
 
Note:  Choose the appropriate cuff to avoid any error caused by gap between cuff and ankle in 
the measurements.  If cuff is too large, the blood pressure measurement may be lower than 
actual value.  If cuff is too small, measurement may be higher than actual value. 
 
6. To attach the appropriate cuff to the cuff hose, insert the hose and turn it clockwise to lock. 
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 7. Wrap the brachial cuffs around bare arms or thin clothing. (When applying the cuff above 
clothing, pull the clothing so that it does not bunch up on the side of the artery.  If the cuff is 
wrapped around the arm with clothing bunched up at the artery site, the blood pressure will 
measure higher than the actual value.)   Place appropriate cuff on each arm (cuffs are marked for 
left and right).   The brachial artery runs down the inside of the arm.  Attach the cuffs so that the 
horizontal artery position mark on the cuff aligns with the artery.  See image below: 
 
 
Apply the cuff with the tubing traveling up the arm towards the shoulder.  Wrap the cuff snugly 
so that 2 fingers can be placed between the cuff and the arm.  At this time, be sure that the index 
line is inside the range shown by the arrow mark.  See image below:  
 
 
 
Note:  If the index line does not go inside the range, use a cuff of another size.  
 141 
 8. Remove socks or stockings for application of ankle cuffs. The cuffs are marked for right and 
left side.  Place the cuffs so that the artery position mark is about two finger widths from the top 
of the medial malleolus on the inside portion of the leg.  See image below: 
   
 
Note: The sensor cuff segment (see image below) must be in contact with the posterior tibial 
artery of the ankle for the purpose of detecting the pulse. 
 
 
 
Wrap the lower ankle velcro wrap first then the upper calf velcro wrap.   Wrap the cuff so that 
there is enough space to fit one finger between the cuff and ankle. 
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Note:  If a section of the index line can be seen through the cuffs window, measurements can be 
taken.  See image below: 
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 9. Application of the ECG (electrocardiogram) clips:  
       
To attach the electrodes to the ECG clip, press and hold the button on the side of the right ECG 
clip and insert one electrode to the right ECG clip.  Release the button to fix the electrode to the 
clip.  Repeat these steps with the left ECG clip.  Remove the protection sheets from all 3 
electrodes. 
 
The wrist clips are marked left and right.  The left sensor has two electrodes and the right sensor 
has one electrode.  Apply the clips to medial side of the forearm placing sensors just above the 
area where the radial pulse is palpated. 
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 10. Application of the PCG (phonocardiogram) sensor: 
 
Take off the protective sheet (light blue) and put it onto the sensor. Remove the cover sheet that 
is on the gel pad side.  There are three places that the PCG sensor can be placed: 
 
a) The 4th intercostal space to the left of the sternum. (#4 on diagram)   
b) The 2nd intercostal space directly over the sternum. (#6 on diagram) 
c) The 3rd intercostal space (centered). (#5 on the diagram)  
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 11. Verify all fields on the participant information screen are completed and select F3 to confirm. 
Note:  Take care to avoid mistakes in entering information and numerical values because this 
information will be used in determining analysis results and cannot be changed after the fact. 
 
12. The measurement screen should now be in view.  Inform the participant to hold still and not 
move while the measurements are in progress. 
 
13. Achieve the following on the screen display before the measure is started:  
ECG: OK status  
PCG: OK status   
Note: It is recommended that at least 3-4 meters be flashing on the PCG level when the 
measurement starts.   While testing can be started even when “OK” is not indicated, the accuracy 
may be reduced. 
 
14. Depress the Blue Start Switch to have the cuffs inflate automatically.  The measurements 
will be recorded for 30-60 seconds and when the measures are complete the cuffs will deflate 
automatically. 
 
15. Evaluate the results on the display screen for accuracy.  Results are automatically printed 
after each run.  The machine will prompt you if waveforms are not adequate and will offer 
corrective suggestions.  Pay attention to screen messages and make changes accordingly (refer to 
pages 90 thru 97 of the Operation Manual for a List of Colin Messages/ Troubleshooting for 
specific errors and how to make adjustments).   
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16. Depress the Orange Stop Switch to return to the ID Input screen.  Re-verify the SWAN IV 
ID and depress the F3/Confirm button.  Repeat steps 12-15 for the start of the 2nd run.   
 
17. Each print out must be assessed for quality and accuracy.  Prior to dismissing the participant 
the numbered areas on the Colin print out (see next page) are to be reviewed for correct data 
entry.  
 
18. On the Clinical Measurements form, complete all the appropriate boxes for each run 
performed and provide comments (if any) from the machine print out.   
 
The following pages contain a sample printout and numbered descriptions of each element on the 
Colin printout. 
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